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The Effects of a Phosphodiesterase Inhibitor on Intraocular Pressure 
and Ciliary Process Cyclic Nucleotide Levels in Rabbits 
Julia Arlene Whiteside 
1986 
This study investigated the effects of a phosphodiesterase inhibi¬ 
tor, HL725 (Hoescht-Roussel Pharmaceutical, Inc.), believed to be selec¬ 
tive for cAMP phosphodiesterase, on intraocular pressure and ciliary 
process cyclic nucleotide levels in rabbits. The albino rabbits used 
in this study demonstrated a reproducible circadian rhythm of IOP when 
housed under standard conditions with a 12:12 light:dark cycle. Topi¬ 
cal applications of HL725, 0.1% and 1% in saline and 1% and 5% in BSS/- 
hydroxypropylmethylcellulose, caused small but significant decreases in 
IOP in the treated eye in comparison to the contralateral control eye. 
Intravitreal injections of HL725, resulting in calculated final intra- 
-10 -3 
vitreal concentrations between 10 and 10 M, caused no change in 
IOP. Intravitreal injections of HL725 resulting in final intravitreal 
-5 -6 
concentrations of 10 and 10 M potentiated the ocular hypotensive 
effect of topically applied isoproterenol 0.01%. HL725 increased cili¬ 
ary process cAMP and cGMP over basal levels, suggesting that it was a 
nonselective inhibitor of cyclic nucleotide phosphodiesterases in cili¬ 
ary processes in the concentration range studied. 
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A. Circadian Rhythms of IOP: An Indication of the Existence of a 
Regulatory Mechanism Controlling IOP 
The observation of a circadian variation of intraocular pressure 
(IOP) in normal eyes and of larger fluctuations of IOP in glaucomatous 
eyes has led investigators to postulate the existence of regulatory 
mechanisms maintaining normal levels of IOP and malfunctions in some 
portion or portions of that regulatory mechanism occurring in glauco¬ 
ma. A daily cyclic variation in human IOP was first noted in glauco¬ 
matous patients in 1898 by Sidler-Huguenin who reported tactile meas¬ 
urements of IOP with two pressure peaks daily, one before sleep and 
another shortly after waking. Several investigators [Maslenikow, 1905; 
Pissarello, 1915; Kollner, 1916; Thiel, 1925] later reported tonometric 
measurements demonstrating that glaucomatous eyes exhibited a pattern 
of a single maximal IOP in the early morning and a minimum pressure in 
the evening. Others [Langley and Swanljung, 1951; Macdonald, 1956; 
Hager, 1958] documented five types of diurnal variation curves: double 
peaking in the morning and again in the early evening, single peaking 
in the morning, single peaking in the early evening, varying sporadi¬ 
cally or irregularly, and essentially flat. In all the studies the 
more common curve was that which peaked in the morning, fell in the 
afternoon, and had a lower peak in the early evening [Langley and Swan¬ 
ljung, 1951; Drance, 1960; Katavisto, 1964], A more recent study 
measuring IOP frequently throughout the twenty-four hour period further 
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characterized the circadian cycle as having its minimum between two and 
four a.m. [Henkind et al., 1973]. Although several patterns of circa¬ 
dian variation could be found in glaucomatous patients, each indivi¬ 
dual's rhythm appeared to be constant unless the sleep-wake cycle was 
changed [Kollner, 1916; Hager, 1958]. 
Diurnal rhythms occur also in normal eyes but with smaller varia¬ 
tions. In 1904 Maslenikow documented that the IOP of normal eyes ex¬ 
hibited a cyclic pattern with variations of IOP averaging 2 mm. Hg., 
significantly less than the fluctuations seen in the IOP of glaucoma¬ 
tous eyes. Later studies [Duke-Elder, 1952; Drance, 1960; deVenecia 
and Davis, 1963; Katavisto, 1964] recorded average diurnal variations 
of IOP for non-glaucomatous patients in the range of 3 to 7.5 mm. Hg.. 
Again the most common IOP curve had a large morning peak, a smaller 
evening peak, and a decline of IOP through the night. The comparison 
of normal and glaucomatous eyes revealed that larger fluctuations in 
IOP occurred in glaucoma, that IOP usually became more labile before 
becoming abnormally elevated, and that the diagnosis of ocular hyper¬ 
tension could be missed if only one measurement of IOP was taken during 
the day [Drance, 1960; Katavisto, 1964]. Physicians were cautioned to 
measure IOP more than once daily in patients having borderline tensions 
and to take into account the circadian pattern when treating ocular 
hypertension. 
Circadian IOP rhythms have been detected also in rabbits, crepus¬ 
cular mammals [Thompson and Worden, 1956] used frequently in ophthalmic 
research. Rabbits kept for eight days in a facility where the light 
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dark schedule corresponded to the sunrise-sunset schedule were trans¬ 
ferred to a lab with constant artificial lighting for the 24-hour 
period of IOP measurements [Vareilles et al., 1977a]. They exhibited a 
pattern of low IOP at night, a sharp rise in IOP between 6 and 8 a.m., 
maintenance of a high IOP throughout the day, and a decline in the ear¬ 
ly evening. A second group of rabbits was kept for seven to ten days 
in a room with a light/dark schedule of 7 a.m. to 5:30 p.m. light/ 5:30 
p.m. to 7 a.m. dark, but was moved to a laboratory with a greater 
light/dark ratio (7:30 a.m. to 11:30 p.m. light/ 11:30 p.m. to 7:30 
a.m. dark) for the measurement period [Katz et al., 1975]. A third 
group entrained on a 5 a.m. to 5 p.m. light/ 5 p.m. to 5 a.m. dark 
schedule was transferred to a measurement laboratory where the arti¬ 
ficial lighting conditions were not specified but the daylight source 
varied according to the season [Bar-Ilan, 1984]. The second group had 
two diurnal peaks of IOP, a smaller one between 8 and 11 a.m. and a lar¬ 
ger one between 4 and 7 p.m., and a minimum recorded between 7 and 9 
p.m. The third group also exhibited two daily peaks, one small peak at 
3 p.m. and a large peak at 10 p.m., with IOP falling between 10 p.m. 
and midnight (no measurments were recorded between midnight and 9 
a.m.). Although a general cycle of high diurnal IOP and low nocturnal 
IOP was seen in all three groups these three studies reported three 
different circadian rhythms. The three patterns may have differed in 
the timing of peaks and troughs and in the shapes of the curves possi¬ 
bly because of the differences in the artificial light-dark schedules 
and sunrise-sunset timing as well as animal behavior patterns. The in¬ 
vestigators pointed to the necessity of careful consideration of IOP 
patterns and documentation of control values in utilizing a rabbit mod- 
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el, but none apparently realized the effect that changes in lighting 
conditions of the measurement environment might have had on the rab¬ 
bits' circadian rhythms. 
Taking into account the importance of entrainment and maintenance 
of a controlled environment for the preservation of circadian rhythms, 
a group of researchers designed an experimental protocol which could 
provide a useful rabbit model for the investigation of circadian 
rhythms of IOP [Rowland et al., 1981]. Measurements were taken without 
changing the lighting conditions by utilizing a far-red range light dur¬ 
ing periods of darkness. The pattern of daily IOP variation was op¬ 
posite to that observed in the three previous studies. Highest IOPs 
were seen during the night and lowest IOPs during the day, with sharp 
rises and falls in IOP occurring at the beginning of darkness and 
light, respectively. The authors demonstrated that the rabbits' cir¬ 
cadian rhythm was preserved in constant darkness but eliminated by con¬ 
stant light, in which the rabbits' IOP pattern became almost flat at a 
mean IOP level. They proposed that a leveling off of IOP at a midrange 
pressure in constant light implied that the mechanisms controlling IOP, 
entrained by the light-dark schedule, acted to increase IOP in darkness 
and decrease it in light. A recent study [Gregory et al., 1985] of the 
circadian rhythm of rabbits, performed under similar experimental con¬ 
ditions employing a well-controlled environment and a long wavelength 
red light, confirmed that IOP is higher in dark and lower in light and 
that the pattern continues in constant dark. By reversing the light- 
dark cycle and documenting a reversal of the IOP cycle they demonstra¬ 
ted that the light-dark schedule was the cue necessary for entrainment 
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of the IOP rhythm. They remarked upon the prolonged persistence of the 
IOP pattern in constant dark as an indication that the rhythm was truly 
circadian with a period close to 24 hours. Both of these investiga¬ 
tions, employing conditions necessary for preservation of circadian 
rhythms, indicated that rabbit IOP circadian pattern, although exempli¬ 
fying a light-dark cycle reverse to that reported for humans, could be 
utilized as a reproducible animal model for the study of factors affect 
ing and controlling the human circadian rhythm of IOP. 
Seasonal as well as diurnal variations in IOP were observed in rab¬ 
bits [Vareilles et al., 1977; Bar-Ilan, 1984]. Normal and glaucomatous 
patients also were reported to have seasonal IOP fluctuations. Season¬ 
al variation in human IOP, with highest IOPs in January and February 
and lowest IOPs in July and August [Blumenthal et al., 1970; Bengtsson, 
1972], were noted to be similar to seasonal changes in other physiolo¬ 
gic parameters such as heart rate, basal metabolic rate, and adrenal 
cortical activity (all observed to have the reverse seasonal pattern 
with values higher in summer than in winter). The analogy between sea¬ 
sonal and circadian IOP variations and cyclic changes in other physiolo 
gic values incited an attempt to explain the cause of these fluctua¬ 
tions by correlating IOP changes with variations in hormonal or other 
biochemical substances in the plasma or CNS. One group of investiga¬ 
tors [Schmerl and Steinberg, 1955] extracted from the CSF two sub¬ 
stances which they named hyperpiesin and miopiesin. They demonstrated 
that hyperpiesin caused an increase in IOP, miopiesin caused a decrease 
in IOP, and that the amount of hyperpiesin and miopiesin in the CSF was 
related to light and dark conditions. In man a higher CSF concentra- 
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tion of miopiesin occurred in light and a higher CSF concentration of 
hyperpiesin occurred in dark. In rabbits, the correlation between con¬ 
ditions of light and dark and CSF concentrations of miopiesin and hyper¬ 
piesin was reversed. From their results they postulated that the ante¬ 
rior pituitary secreted hyperpiesin, the posterior pituitary stored hy¬ 
perpiesin and transformed it to miopiesin via a catalyst (activated by 
light and heat), that hyperpiesin caused an increased IOP via parasympa- 
thetically mediated vasodilation and miopiesin caused a decreased IOP 
via sympathetically mediated vasoconstriction, and that under normal 
circumstances the CSF contained both substances in amounts which provid¬ 
ed a physiologic balance and a normal level of IOP. Another group of 
investigators [Weitzman et al., 1975] studied the relationship between 
plasma cortisol concentrations (known to be preceded by changes in plas¬ 
ma ACTH concentrations) and IOP. (This relationship was of particular 
interest because of the known parallelism between circadian curves of 
plasma catecholamine and cortisol concentrations [implying that adreno- 
medullary and adrenocortical activity might both be influenced by ACTH 
secretion circadian rhythms] and because of information implicating 
neural transmitter substances in the regulation of other endocrine func¬ 
tions [Eleftheriou, 1974].) They demonstrated a similarity between the 
circadian patterns of the two levels, with the plasma cortisol and the 
IOP 24-hour curves having a phase difference of three hours between the 
mean nadir and zenith, the cortisol curve preceding the IOP curve. The 
dexamethasone suppression test ablated the cortisol but not the IOP 
curve, indicating that the relationship between the two curves was cor¬ 
relative, not causative. (The lack of a causative relationship is not 
surprising in light of the present knowledge that IOP is affected by 

7 
the light-entrained [Rowland et al., 1981; Gregory et al., 1985] "Y" 
pacemaker and plasma cortisol by the "X" pacemaker [Moore-Ede et al., 
1982]). Evidence from these two studies, and the analogy between cir¬ 
cadian rhythms of IOP and of many other physiologic functions which 
were known to be controlled by the hypothalamus, suggested but did not 
prove that neural and humoral control of IOP might exist. 
B. Circadian Rhythms of IOP: Studies of Aqueous Humor Dynamics 
Ophthalmologists have attempted to explain not only the possible 
central and hormonal causes of circadian fluctuations in IOP but also 
the importance of changes in aqueous humor dynamics. Although Stepanik 
[1954] found that outflow resistance was highest when the maximum IOP 
occurred during the diurnal rhythm and Drance saw a diurnal variation 
of outflow facility (C) in glaucomatous patients. Grant [1955] reported 
an unchanging outflow facility throughout the circadian cycle and subse 
quent studies [Newell and Krill, 1964; Radnot et al., 1970] were unable 
to confirm a definite or statistically significant relationship between 
the variations of IOP and of outflow facility. In contrast, investiga¬ 
tions of aqueous humor formation (AHF) have shown that changes of AHF 
correspond to changes in IOP in the circadian rhythm [Grant, 1955; Eric 
son, 1958; Reiss et al., 1984]. The results of these few experiments, 
along with the report of the constancy of episcleral venous pressure 
(EVP) [Linner, 1956], suggest that of the parameters: AHF, C, and EVP, 
aqueous humor formation plays the most important role in circadian var¬ 
iations of IOP. A circadian rhythm of uveoscleral outflow, another 

component of aqueous humor dynamics [Bill, 1965 and 1970] which ac¬ 
counts for only a small percentage of total outflow in man [Jocson and 
Sears, 1971], has not been shown. 
Recent studies of AHF by fluorescein clearance techniques have re¬ 
sulted in possible explanations of the role of AHF in circadian IOP 
changes and for the neurohumoral regulation of circadian IOP varia¬ 
tions. Measurements of AHF between 8 a.m. and 1 p.m., noon and 5 p.m., 
and midnight and 5 a.m., showed rates of 3.1, 2.4, and 1.6 micro- 
l./min., respectively [Brubaker et al., 1984; Reiss et al., 1984]. AHF 
during the morning hours was twice as rapid as the flow rate at night 
during sleep; an intermediate rate of flow was seen in the afternoon 
hours. Subjects who were sleep-deprived demonstrated a nighttime AHF 
of 2.3 microl./min., higher than the AHF rate (1.6 microl./min.) of 
subjects whose sleep was undisturbed. The AHF of sleep-deprived pa¬ 
tients may have been higher than the normal nighttime AHF because sleep 
is required for "maximum suppression of aqueous flow" [Reiss et al., 
1984], or because the subjects' regular circadian pattern of AHF was 
changed by exposure to light or the nocturnal pattern was altered by 
activity and eating during the period of time of normally undisturbed 
sleep. The authors noted that the AHF rate during sleep was comparable 
to the AHF rate which they had documented in patients treated with car¬ 
bonic anhydrase inhibitors and beta-blockers. Shortly thereafter it 
was found that during the day timolol and acetazolamide decreased nor¬ 
mal daytime AHF 30 and 20%, respectively, while epinephrine increased 
daytime AHF 15%. During the night neither timolol nor acetazolamide 
had any significant effect on AHF, while epinephrine increased the 
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normal flow of AHF during sleep by 47% [Topper and Brubaker, 1985a and 
b]. During the day in the supine position subjects had an AHF 12% less 
than the normal daytime AHF. Based upon these results and the know¬ 
ledge that plasma epinephrine concentrations are reduced during sleep 
and in the supine position, the authors postulated that the circadian 
rhythm of AHF is caused by normally circulating epinephrine stimulating 
aqueous humor production and that the mechanism of action of timolol 
and other beta-blockers (a molecular mechanism which has not been eluci¬ 
dated despite many hypotheses proposed to date) was to block AHF stimu¬ 
lation by epinephrine or another endogenous mediator. 
C. A Regulatory Mechanism for Control of TOP: The Hypothesis of 
Centrally Mediated Control 
The hypothesis that epinephrine or another catecholamine is in¬ 
volved in the control of IOP is not a new one. A role for the sympa¬ 
thetic nervous system in IOP control was postulated as early as the 
1860's when cervical sympathetic ganglionectomy [Wegner, 1866; Hertel, 
1900] and cervical sympathetic nerve stimulation [vonHippel and Gruen- 
hagen, 1870] resulted in a decrease in IOP. The use of adrenaline 
(epinephrine) for the treatment of glaucomatous patients was based on 
the belief that elevated IOP in glaucoma resulted from a sympathetic 
neurosis of the uveal vessels causing vascular atony and increased 
blood volume [Hamburger, 1914 and 1923]. Darier [1900] gave subcon¬ 
junctival injections and Hamburger [1923] gave topical applications of 
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epinephrine to patients with glaucoma. Thiel [1931] believed that a 
disturbance of regulation of intraocular circulation and therefore 
blood-tissue fluid exchange was one of the causes of glaucoma. Duke- 
Elder [1932] pointed to the presence of sympathetic fibers in the uveal 
tract as evidence for control of intraocular vessel tone by the sympa¬ 
thetic nervous system. During that period of time many ophthalmol¬ 
ogists believed that an abnormality in the function of the sympathetic 
fibers in the eye was responsible for IOP elevations [Elwyn, 1938]. 
Based upon these authors' postulates, the observation that diurnal 
rhythms of IOP were comparable to changes in other "vegetative func¬ 
tions," and the evidence for regulation of other normal physiologic 
values by a central mechanism, Elwyn [1938] formulated an hypothesis 
for an IOP regulatory mechanism analogous to that of other physiologic 
functions. This consisted of an hypothalamic control center, neural 
and humoral "channels of influence," and an effector organ (in this 
case, the eye). According to his hypothesis the effects of the neural 
"channels of influence" would be carried from the hypothalamus through 
the brainstem and spinal cord and thence through the sympathetic and 
parasympathetic nervous systems to the fibers ending in the eye. The 
humoral regulation would occur by the hypothalamus exerting effects on 
the hypophysis to secrete hormones into the circulation from whence 
they would be carried to the eye. Normal IOP would be maintained by 
impulses sent from theoretical pressure sensors in the eye (whenever 
IOP wandered outside a normal range) to the control center from which, 
in response, hormones or nervous impulses would be delivered back to 
the eye to reestablish a normal IOP. Elwyn furthermore proposed that 
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some abnormality in this regulatory mechanism was the cause of glauco¬ 
ma. He compared the early increasing lability of IOP and subsequent 
elevated IOP with the earlier large fluctuations and subsequent eleva¬ 
tions of blood pressure and blood glucose. He believed that glaucoma, 
as well as systemic hypertension and diabetes, resulted from changes in 
the regulatory mechanism which caused first increasingly variable and 
later abnormally high IOP, blood pressure, and blood glucose. 
Clinical observations of glaucoma patients led Hess, in 1946, and 
other physicians [Zondek and Wolfsohn, 1947; Magitot, 1947] to hypo¬ 
thesize the existence of similar IOP regulatory mechanisms with the 
diencephalon as the center of control. Attempts to locate this center 
and to define its influence on IOP were made by stimulating areas of 
the diencephalon and hypothalamus of rabbits and cats [Schmerl and 
Steinberg, 1950; Nagai et al., 1951; Takagi, 1952; Weinstein, 1954; 
vonSallman and Lowenstein, 1955; Gloster and Greaves, 1957; Duke-Elder, 
1957]. None of these investigators identified conclusively a region of 
the CNS which appeared to exert prolonged influences on IOP separate 
from its effects on blood pressure, extraocular muscle contraction, ser¬ 
um osmolarity, or other factors. 
Researchers continued to hypothesize that the hypothalamus might 
be the controlling site for changes in IOP [Waitzman, 1971] and contin¬ 
ued to search for some form of hypothalamic control on IOP. In the 
attempts to corroborate the existence of an osmotic central regulatory 
mechanism for IOP control, mediated by the hypothalamic osmoreceptors 
and "efferent" fibers of the optic nerve, studies were performed on pa- 
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tients with unilateral optic nerve lesions and on animals after unilat¬ 
eral optic nerve transection [Riise and Simonsen, 1969; Krupin et al., 
1970]. Even though optic nerve efferent fibers had been traced from 
the anterior hypothalamus [Sacks and Lindenburg, 1969] and the rabbit 
and human eyes with transected optic nerves did show altered responses 
to osmotic agents in comparison to eyes with intact optic nerves, the 
results of these studies only suggested, did not prove, that hypothal¬ 
amic osmoreceptors might be involved in IOP control. 
Manipulation of the CNS by direct stimulation of the hypothalamus 
and by induction of osmotic changes failed to locate an IOP control 
center in the CNS. Attempts to demonstrate a pressure sensor in the 
eye or a regulatory feedback mechanism were equally unsuccessful. In¬ 
traocular infusion experiments, in which IOP was varied at the same 
time that IOP and C were monitored, did not indicate the presence of 
any apparent feedback mechanism for the maintenance of a normal level 
of IOP [Sears, I960]. Pseudofacility, the pressure-sensitive portion 
of AHF detected as a facility by tonographic measurements [Barany, 
1963], was believed by some to be a local IOP regulatory mechanism act¬ 
ing to diminish IOP increases by decreasing ultrafiltration (and there¬ 
fore AHF) whenever IOP increased [Barany, 1963; Bill and Barany, 1966; 
Kupfer and Sanderson, 1968; Bill, 1968; Brubaker, 1970]. As the sup- 
pressability of aqueous humor formation, pseudofacility was postulated 
also to be a manifestation of a feedback and central regulatory mech¬ 
anism for IOP control [Bill,1969]. Ultrafiltration appears to be unim¬ 
portant in AHF [Caprioli, in press], and pseudofacility may not be an 
extant phenomenon [Moses, 1985]. 

13 
The inability to demonstrate prolonged IOP changes by manipulation 
of the CNS does not preclude the existence of an IOP central regulatory 
mechanism. In fact, the IOP circadian rhythm, known in rabbits to be 
entrained by the zeitgeber light [Rowland et al., 1981; Gregory et al., 
1985], provides evidence for a control center located in the CNS. In 
mammals the suprachiasmatic nuclei (SCN) have been shown to be the site 
of the primary pacemaker associated with the light-dark cycle [Moore- 
Ede et al., 1982 & 1983]. This pacemaker appears to be entrained by 
light signals transmitted through the retinohypothalamic tract (RHT) 
and to control circadian rhythms of skin temperature, urine calcium 
excretion, plasma growth hormone levels, rest and activity, sleep and 
waking, and drinking. In humans a similar cluster of neurons, located 
more laterally in the anterior ventral hypothalamus above the third 
ventricle, is believed to contain the light-dark cycle associated 
pacemaker [Moore-Ede et al., 1982 & 1983], and a retinosuprachiasmatic 
pathway may be the route of transmission of light signals entraining 
the central circadian pacemaker [Sadun et al., 1984]. The demon¬ 
stration of light as the zeitgeber for entrainment of the IOP circadian 
rhythm [Rowland et al., 1981; Gregory et al., 1985] indicates that a 
circadian timing system with a pacemaker located in the CNS exerts 
control of IOP. The IOP increases of the circadian cycle in rabbits 
appear to be mediated by adrenergic innervation [Gregory et al., 1985]. 
D. A Regulatory Mechanism for Control of IOP: Indications of 
Hormonal Influences on IOP 
There is evidence substantiating the existence of Elwyn's humoral 
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"channels of influence" [1938] as well as the control center located in 
the CNS. The possibility of hormonal control of IOP was suggested by 
the clinical observation of low IOP in patients with pregnancy and myo¬ 
tonic dystrophy, conditions associated with elevated levels of circu¬ 
lating hCG and FSH, respectively [Imre, 1922; DeGrosz, 1937; Horven and 
Gjonnaess, 1974; Brand, 1955; Burian and Burns, 1967], Numerous other 
studies correlating ocular hypotensive and hypertensive states with 
physiologic hormonal changes and with diseases characterized by abnorm¬ 
al hormone levels [Kass and Sears, 1977] suggested a role for various 
glycoprotein and steroid hormones in the regulation of IOP. Signifi¬ 
cant decreases of IOP in menopausal glaucomatous patients [Niebroj et 
al., 1971], in infertile females [Rubin, 1985], and in rabbits [Gier- 
kowa et al., 1976; Rubin, 1985] occurred when hCG was administered in¬ 
tramuscularly. Intravitreal injections of the glycoprotein hormones 
FSH, LH, hCG, and TSH, but not progesterone, caused decreases in IOP of 
rabbits with a potency order: FSH = LH > TSH > LH [Sears and Mead, 
1983]. These investigations confirmed the influence of glycoprotein 
hormones on IOP and the possibility of hormonal regulation of IOP. 
E. A Regulatory Mechanism for Control of IOP: The Role of the 
Adrenergic Nervous System 
Sympathetic control of IOP was postulated as early as the nine¬ 
teenth century [Wegner, 1866; vonHippel and Gruenhagen, 1870]. Since 
that time, years of experience with adrenergic agents in treating 
glaucoma and in investigating their effects on components of aqueous 
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humor dynamics have led to further conjectures of the role of the sym¬ 
pathetic nervous system in local neural IOP control. Several factors 
have caused considerable confusion in interpreting results of the in¬ 
numerable investigations of adrenergic agents' effects on IOP. It has 
been difficult to separate the complex interactions between intraocular 
structures which bring about changes in individual components of aque¬ 
ous humor dynamics and result in a net change in IOP. It has been even 
more difficult to draw conclusions from (or to make comparisons be¬ 
tween) experiments which differ in almost every aspect of design, in¬ 
cluding routes of drug administration (and therefore pharmacodynamics), 
techniques of aqueous humor dynamics measurement, animal species (and 
therefore intraocular structures and adrenergic receptors), and timing 
of measurements [Mishima, 1982; Sears, 1984]. Within this text a com¬ 
prehensive review will not be attempted but instead an historical per¬ 
spective and overview of the resulting theories will be presented. 
In the 1950's Goldmann [1951] and Weekers [1955] demonstrated that 
adrenaline (epinephrine) lowered IOP and AHF in humans without affect¬ 
ing outflow facility. In contrast, the results obtained from tonography 
and long term follow-up of glaucomatous patients treated with epine¬ 
phrine suggested that it reduced IOP by increasing C. Garner [1959] 
first noticed in a few patients that outflow facility was increased, 
and other investigators subsequently reported short and long term in¬ 
creases in C [Becker, 1961; Ballantine, 1961; Galin et al., 1966; 
Kronfeld, 1971]. The effect of epinephrine in humans was described 
then as having three components: (1) an early decrease in AHF, (2) an 
early increase in C, and (3) long term progressively increasing C 
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[Sears, 1966]. The early decrease in AHF was presumed to be secondary 
to decreased blood flow to the ciliary processes [Sears, 1966], possib¬ 
ly by alpha-adrenergically mediated vasoconstriction of uveal vessels 
[Mishima, 1982], although recent studies suggest that decreased blood 
flow to the iris-ciliary body is not short term [Caprioli et al., 
1984]. 
Assuming episcleral venous pressure (EVP) is not affected by 
beta-adrenergic drugs (and is approximately 9 mm.Hg.) [Mishima, 1982] 
and that uveoscleral outflow is only a small percentage of total 
outflow in humans [Jocson and Sears, 1971], changes in IOP can be 
attributed to the sum of changes in outflow resistance (R) and in 
aqueous humor formation (AHF). In order to interpret the effects of 
adrenergic drugs on IOP one can calculate reduction ratios of outflow 
pressure and of outflow resistance from human experimental data 
[Mishima, 1982]. From the relationship: 
{ deltalOP/(IOP-EVP) } = { deltaR/R + deltaAHF/AHF }, 
[where: (1) outflow pressure = (IOP-EVP);(2) R = 1/C ; (3) delta 
IOP/(IOP-EVP) = reduction ratio of outflow pressure; and (4) deltaR/R = 
reduction ratio of outflow resistance or reciprocal of reduction ratio 
of outflow facility], one can see that a high correlation between the 
reduction ratios of outflow pressure and of outflow resistance would 
indicate that changes in outflow resistance (the reciprocal of C) 
primarily are responsible for changes in IOP. A poor correlation be¬ 
tween outflow pressure and outflow resistance reduction ratios would 
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indicate a significant role for AHF in causing the IOP changes. An¬ 
alysis of data from clinical investigations of epinephrine's early and 
late hypotensive effects showed a high correlation between the outflow 
pressure and outflow resistance reduction ratios for almost all stud¬ 
ies. Short and long term increases in C appear therefore to be respon¬ 
sible for the short and long term hypotensive effects of epinephrine 
[Mishima, 1982]. The early increase in C may be caused by alpha- and 
beta-adrenergic effects, and the long term progressively increasing C 
is perhaps related to the activation of lysosomal hyaluronidase and 
therefore to metabolism of trabecular meshwork glycosaminoglycans de¬ 
creasing outflow [Hayasaka and Sears, 1978]. 
Evidence for the acute alpha-adrenergic effect of epinephrine on C 
was obtained from a series of cervical sympathetic ganglionectomy exper 
iments on rabbits. Early ganglionectomy studies demonstrated a de¬ 
crease in IOP, and measurements of C along with IOP suggested that a de 
crease in AHF caused the prolonged decrease in IOP seen hours to days 
after ganglionectomy [Linner and Prijot, 1955; Lieb et al., 1958]. 
Langham and Taylor [1959 and 1960] and Sears and Barany [1960] demon¬ 
strated on the contrary that the decrease in IOP was secondary to an 
increase in C and that the effect was alpha-adrenergically mediated 
[Sears and Barany, I960]. Further investigations indicated that post¬ 
ganglionic section resulted in norepinephrine release from the iris in¬ 
to the aqueous humor where it caused an alpha-mediated increase in out¬ 
flow, and that the increased C and decreased IOP seen in eyes with an 
intact sympathetic system was short term and slight because of the in¬ 
activation of norepinephrine via uptake and binding by the iris [Bara- 
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ny, 1962; Rosser and Sears, 1963; Eakins, 1963; Eakins and Eakins, 
1964; Sears and Sherk, 1964; Sears et al., 1966; Sears and Gillis, 
1967; Rosser and Sears, 1968]. The short term increase in outflow fac¬ 
ility caused by epinephrine in humans and rabbits was, therefore, at 
least partially mediated by alpha-adrenergic effects on the outflow 
channels [Sears, 1975]. 
Conflicting results have been obtained for the possible role of 
beta-mediated effects on outflow in rabbits and man. In the rabbit a 
series of experiments [Neufeld et al., 1972; Neufeld et al., 1973; 
Neufeld and Sears, 1974; Neufeld et al., 1975] suggested that epine¬ 
phrine affected the outflow channels and decreased IOP by an increase 
in the aqueous humor cyclic 3',5'-adenylmonophosphate (cAMP) concen¬ 
tration, probably via a beta-receptor mediated mechanism [Sears, 
1975]. A later study showing blockade by timolol of epinephrine's 
increase in aqueous humor cAMP concentration but not of epinephrine's 
hypotensive response [Boas et al., 1981] suggested, however, that the 
relationship between increased aqueous humor cAMP concentration and 
decreased IOP was not a causal one. Other investigations have provided 
evidence both for and against beta-adrenergic mediation of augmented 
outflow facility in the rabbit, and the issue has yet to be resolved 
[Mishima, 1982; Sears, 1984]. Experiments conducted in humans provided 
equally conflicting results concerning the possible role of the beta- 
receptor in increasing C [Mishima, 1982]. Epinephrine appears to in¬ 
crease uveoscleral outflow in humans [Townsend and Brubaker, 1980], and 
this effect may be secondary to beta-stimulated relaxation of the cil¬ 
iary muscle [Townsend and Brubaker, 1980; Mishima, 1982]. Although 
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both alpha- and beta-receptor mechanisms may be involved in epineph¬ 
rine's effects on C, the only conclusive evidence thus far indicates 
that the moderate early increases in C are caused by alpha-adrenergic 
stimulation [Sears, 1984; Caprioli, 1985]. 
Investigations of epinephrine's effects on AHF have provided re¬ 
sults as conflicting as those on the role of the beta-receptor in out¬ 
flow mechanisms. Since Goldmann's demonstration of epinephrine's abil¬ 
ity to decrease AHF in man in 1951, numerous determinations of AHF have 
been made in rabbits and in man. Fluorophotometric techniques using 
topical and systemic administration of fluorescein have been utilized. 
Some investigators have cannulated the anterior chamber, possibly re¬ 
sulting in slight blood-aqueous barrier breakdown as demonstrated by 
slightly increased aqueous humor protein concentrations [Mishima, 
1982]. As many studies have demonstrated decreased AHF [Goldmann, 
1951; Weekers, 1955; Gaasterland et al., 1973; Takase, 1976; Nagataki, 
1977; Green and Padgett, 1979; Araie and Takase, 1981; Miichi and Naga¬ 
taki, 1982] as have shown increased AHF [Townsend and Brubaker, 1980; 
Nagataki and Brubaker, 1981; Schenker et al., 1981; Thomas and Epstein, 
1981; Lee et al., 1983; Topper and Brubaker, 1985a and b] after epineph¬ 
rine treatment of humans and rabbits. The different results obtained 
may be a reflection of the differences in experimental design (animal 
species used, timing of measurements, dosage and route of administra¬ 
tion) as well as the limitations and sources of error of each fluoro- 
metric method [Mishima, 1982; Sears, 1984]. After a review of the lit¬ 
erature examining the techniques and timing of measurements, several 
authors have concluded that epinephrine's effects on AHF probably in¬ 
clude an early increase followed by a prolonged decrease in AHF [Mishi- 

20 
ma, 1977; Townsend and Brubaker, 1980; Sears, 1984]. It is apparent, 
however, that more carefully planned and extensive studies need to be 
done to characterize the time sequence of its effects (short and long 
term components as well as variation at different periods of time in 
the circadian rhythm) and the quality of its effects (small or large, 
hypotensive or hypertensive) and to clarify the alpha- and beta-re¬ 
ceptor mechanisms involved [Mishima, 1982]. 
Other explanations have been proposed for the mechanism of action 
of epinephrine. One theory, based upon observations of a decrease in 
epinephrine's hypotensive effectiveness caused by indomethacin, sug¬ 
gests that epinephrine's IOP lowering ability may be mediated partially 
by prostaglandins or other cyclooxygenase products [Bhattacherjee and 
Hammond, 1977; Camras et al., 1985]. Another postulation was that epi¬ 
nephrine's delayed effects were caused by beta-adrenergic desensitiza¬ 
tion. Neufeld et al. [1978] documented a decrease in iris-ciliary body 
beta-receptors following repeated treatment of rabbits with epineph¬ 
rine. Mittag and Tormay [1981] showed that a few doses of epinephrine 
could cause uncoupling of adenyl cyclase (AC) from its activating sys¬ 
tem by decreasing the guanyl nucleotide regulatory protein activity. 
Bartels et al. [1983] compared the IOP and beta-receptor population 
effects caused by epinephrine and timolol and concluded that epineph¬ 
rine has two IOP-lowering effects: an early beta-agonism and a late 
beta-adrenergic desensitization. The late beta-adrenergic desensiti¬ 
zation was hypothesized to cause a decrease in AHF in a manner similar 
to the AHF decline caused by the beta-blocker timolol [Mittag and Tor- 
may, 1981; Bartels et al., 1983]. 
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Information on the effects of norepinephrine, a mixed alpha- and 
beta-adrenergic agonist with predominantly alpha effects, was derived 
not from treatment of glaucomatous patients but from a series of cer¬ 
vical sympathetic ganglionectomy experiments. As previously outlined, 
norepinephrine was shown to be stored in adrenergic nerve terminals lo¬ 
cated primarily in the iris and to be released by degenerating nerve 
terminals shortly after postganglionic sympathetomy, causing an alpha- 
mediated increase in outflow facility. In an eye with intact sympa¬ 
thetic innervation the iris functions to inactivate norepinephrine by 
uptake and binding [Sears, 1975]. 
Despite its known ocular hypotensive effect, isoproterenol, an ad¬ 
renergic agonist with primarily beta effects, has been studied less ex¬ 
tensively than epinephrine because of the concern for its primary side 
effect, systemic tachycardia. When Weekers [1955] investigated a group 
of sympathomimetic amines along with adrenaline (epinephrine) he con¬ 
cluded that adrenaline lowered IOP by reducing AHF via a sympathetic 
stimulatory effect independent of the vasoconstriction. He based his 
conclusion on tonographic demonstration of unaltered C, fluorometric 
evidence for decreased AHF, clinical observation of short term conjunc¬ 
tival vasoconstriction in contrast to longer term tension reduction, 
and experimental documentation of isoproterenol's tension-lowering ef¬ 
fect (similar to adrenaline's) without adrenaline's associated vasocon¬ 
striction and mydriasis. He theorized therefore that isoproterenol 
must lower IOP via a sympathetically stimulated mechanism causing a de¬ 
crease in AHF. Several authors supported the conjecture that isoproter¬ 
enol reduced IOP by reducing AHF with the demonstration of lowered IOP 
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and unaltered C [Eakins, 1963; Ross and Drance, 1970; Langham et al., 
1971; Gaasterland et al., 1973] as well as decreased AHF [Gaasterland 
et al., 1973; Takase, 1976]. Although some investigators have shown 
that isoproterenol may slightly increase C [Eakins and Ryan, 1964; Bon- 
omi, 1964; Gnadinger and Barany, 1964; Lorenzetti, 1971] (especially at 
higher concentrations where it could exert mild alpha effects) its pri¬ 
mary role appears to be in decreasing AHF, as further supported by its 
ability to decrease IOP in rabbits with complete outflow obstruction 
[Bonomi et al., 1964]. A review of studies conducted in humans, compar¬ 
ing the reduction ratios of outflow pressure and outflow resistance, al¬ 
so supports the contention that isoproterenol reduces IOP without in¬ 
creasing C [Mishima, 1982]. Unfortunately isoproterenol's clinical use¬ 
fulness has been limited not only by its toxic effects of systemic 
tachycardia and local hyperemia [Sears, 1982] but also by its decreased 
effectiveness when used chronically [Ross and Drance, 1970]. 
The clinical and experimental work with epinephrine, norepineph¬ 
rine, and isoproterenol demonstrated that adrenergic agonism may lower 
IOP through effects on components of aqueous humor dynamics, including 
inflow, conventional outflow, and uveoscleral outflow, although EVP 
apparently is not changed at least by beta-adrenergic agonists [Mish¬ 
ima, 1982]. Early identification of adrenergic nerves in the ocular 
tissues, including the chamber angle and ciliary processes [Amsler, 
1955; Holland et al., 1957; Laties and Jacobowitz, 1964; Ehinger, 
1966], added support to the belief in adrenergic regulation of IOP, but 
later investigations failed to clarify the mechanistic details of the 
role of the adrenergic agonists in controlling IOP. It is difficult to 
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define specific effects or to locate sites of action of adrenergic a- 
gents based only on pharmacologic and physiologic studies in humans and 
other animals, because of complexities of ocular tissue interactions 
and pharmacodynamics, species differences of ocular tissue adrenergic 
receptors, and the limits of available measurement techniques [Mishima, 
1982; Sears, 1985]. 
The issue of the adrenergic nervous system's role in controlling 
IOP became more enigmatic after discovery of the ocular hypotensive ef¬ 
fects of beta-blockers. In 1960 Sears and Barany demonstrated that di- 
chloroisoproterenol, the first known beta-blocker, increased outflow 
facility. The cause of its effect on C and IOP became uncertain, how¬ 
ever, when it was discovered to have intrinsic sympathomimetic activ¬ 
ity. In 1967 Phillips et al. noted a lowered IOP in patients treated 
with intravenously administered propranolol, a beta-blocker with mem¬ 
brane stabilizing activity and no partial agonist activity. Subsequent 
ly numerous studies confirmed that propranolol, when administered intra 
venously, orally, or topically, caused a decrease in IOP although its 
side effects of ocular discomfort and local anesthesia prohibited its 
topical use [Wettrell, 1977]. Propranolol and other beta-blockers, in¬ 
cluding the cardioselective (beta ) beta-blockers, have been shown to 
1 
decrease IOP in humans as well as rabbits [Boger, 1979; Lotti et al. 
1984]. Beta-blockers have had greater and more consistent hypotensive 
action in hypertensive than normal rabbits and in general have more 
pronounced effects on IOP in humans than in rabbits [Lotti et al., 
1984]. Beta-blockers reduce IOP by decreasing AHF [Takats et al., 
1972; Yablonski et al., 1978; Coakes and Brubaker, 1978; Reiss and 
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Brubaker, 1983; Lotti et al., 1984; Araie and Takase, 1985]. 
Of the many beta-blockers in existence timolol, a nonselective 
(beta and beta ) beta-blocker without intrinsic sympathomimetic 
1 2 
activity or membrane stabilizing activity, has been employed most. It 
has been shown to (1) lower IOP in normal [Katz et al, 1976] and in 
glaucomatous [Zimmerman and Kaufman, 1977] eyes, (2) be more effective 
in lowering IOP than epinephrine or pilocarpine [Zimmerman and Boger, 
1979], (3) lower IOP in the contralateral eye when applied topically 
[Lotti et al., 1984], (4) bind reversibly to ocular pigment thereby 
prolonging its availability to act in the eye [Bartels et al., 1983], 
and (5) have a potency eleven times that of propranolol [Takase and 
Araie, 1980]. Its clinical attractiveness is only minimally diminished 
by "short-term escape" and "long-term drift" [Zimmerman and Boger, 
1979; Boger, 1983]. Some authors have attributed timolol's decreased 
effectiveness in the short term to the well-known phenomenon of beta- 
receptor density modulation as a self-controlling mechanism in the pres¬ 
ence of beta-agonists or antagonists [Boger, 1983]. Indeed, an in¬ 
crease in beta-receptors in the cornea and the iris-ciliary body fol¬ 
lowing prolonged treatment with timolol has been documented, but the 
tissues did not appear to be able to synthesize more cAMP (when stimu¬ 
lated by epinephrine) despite increased receptor density [Neufeld et 
al., 1978]. The causes of the short-term escape as well as the long¬ 
term drift remain unknown [Caprioli, 1985], and despite these character¬ 




Timolol acts, as do other beta-blockers, by lowering AHF [Yablon- 
ski et al., 1978; Coakes and Brubaker, 1978; Lotti et al., 1984; Topper 
and Brubaker, 1985]. How can the paradox of beta-agonists and antag¬ 
onists both resulting in lowered AHF [Wettrell, 1977] be explained? 
Some investigators believe that timolol acts by beta-blockade alone to 
decrease IOP [Liu, 1983], although this theory is dependent on the dem¬ 
onstration of existence of endogenous adrenergic tone (from circulating 
epinephrine or another catecholamine) keeping AHF high in order for be¬ 
ta-blockade to cause a decreased AHF [Neufeld et al., 1983; Topper and 
Brubaker, 1985]. Others have documented more evidence arguing against 
timolol acting to lower AHF and IOP by beta-blockade: (1) higher concen¬ 
trations of timolol are needed to lower IOP than to block beta-recep¬ 
tors [Vareilles et al., 1977b]; (2) d-timolol, a stereoisomer of timo¬ 
lol with significantly less beta-blocking activity than 1-timolol in 
the eye [Liu et al., 1983] as well as other tissues, significantly low¬ 
ers IOP in patients with ocular hypertension [Keates and Stone, 1984]; 
and (3) there is no correlation between the beta-blockers' hypotensive 
effectiveness, its antagonism of isoproterenol's hypotensive effect, 
its antagonism of isoproterenol's adenyl cyclase stimulation, and 
ciliary process beta-receptor binding and blocking potencies [Gregory 
et al., 1981; Schmitt et al., 1981; Sears and Mead, 1983; Lotti et al., 
1984]. These authors have proposed that beta-receptors in the eye may 
be different from other systemic beta-receptors [Schmitt et al., 1981] 
or that timolol acts in the eye by another mechanism than beta-blockade 
[Sears and Mead, 1983]. Although it is unlikely that beta-receptors in 
the eye differ from those in the rest of the body [Sears and Mead, 
1983] it is possible that ocular tissues respond differently to beta 
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blockers than do other tissues, as suggested by the contrast between 
the decreased ocular hypotensive effects and the increased systemic 
hypotensive effects associated with prolonged usage of beta-blockers 
[Boger et al., 1983]. Some beta-blockers prevent the activation of 
phosphodiesterase by calmodulin and of guanyl cyclase by nitroso com¬ 
pounds in the heart [Kudo & Nazawa, 1985]. It is possible that in the 
eye as in the heart beta-antagonists act not by blocking beta-receptors 
but by affecting a cellular enzyme such as a phosphodiesterase or gua¬ 
nyl cyclase. 
F. A Regulatory Mechanism for Control of IOP: The Potential Role of 
the Adenyl Cyclase-Receptor Complex 
What then are the possible regulatory mechanisms, central neural, 
neurohumoral, or hormonal, which could control IOP and result in the 
large fluctuations of IOP seen in the circadian rhythm? Light entrain¬ 
ment of the IOP circadian rhythm pointed to the SCN as the centrally- 
located pacemaker of the circadian system affecting IOP. Neurohumoral 
and hormonal local regulatory mechanisms were suspected because adren¬ 
ergic agonists and antagonists as well as some glycoprotein hormones 
were shown to lower IOP. Pharmacologic doses of epinephrine and other 
agents were shown to cause changes in outflow facility which were small¬ 
er than the variations of IOP seen in the circadian pattern [Sears et 
al., 1981; Caprioli and Sears, 1984], and both adrenergic agonists and 
antagonists were known to cause changes in AHF. It therefore appeared 
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that AHF was the component of aqueous humor dynamics most affected by 
the hypothetical regulatory mechanism and most likely to be responsible 
for the circadian rhythm of IOP, consistent with the earlier conclusion 
of Katavisto [1964] that AHF plays the most important role in diurnal 
variations of IOP. 
In order to identify a possible mechanism of AHF and IOP regula¬ 
tion a system devoid of all the complexities encountered with in vivo 
studies was needed. Animal and human ciliary process tissue provided 
one such in vitro system in which the effects of adrenergic drugs and 
other agents could be determined. Investigations utilizing enzyme stim¬ 
ulation, pharmacologic binding, and fluorescent analogue localization 
techniques resulted in the discovery of adenyl cyclase-coupled beta- 
adrenergic receptors in ciliary process tissue. Correlations between 
in vitro AC stimulation and in vivo AHF diminution caused by adrenergic 
agonists and other compounds led to a theory of regulation of IOP by 
the ciliary epithelial adenyl cyclase receptor complex. 
CyclicAMP phosphodiesterase was found in rabbit ciliary process 
tissue in 1966 [Shanta et al, 1966]. Shortly thereafter AC was identi¬ 
fied in the same tissue, and its activation by catecholamines, KCl, 
NaF, and PGE1 was established [Waitzman & Woods, 1971]. The order of 
AC stimulatory potency of the catecholamines (isoproterenol = epineph¬ 
rine > norepinephrine = phenylephrine) was characteristic of a beta- 
adrenergic pattern [Waitzman and Woods, 1971] and suggested that the AC 
present in ciliary processes might be associated with beta-receptors in 
a fashion similar to the AC-catecholamine receptor coupling known to 
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occur in other tissues [Robison et al., 1967]. 
Pharmacologic binding studies demonstrated the presence of adrener 
gic receptors in the membranes of homogenized rabbit iris-ciliary body 
[Neufeld and Page, 1977]. With a fluorescent propranolol analogue, be¬ 
ta-receptors were localized to ciliary epithelial membranes, ciliary 
processes, and episcleral limbal blood vessel walls in the rabbit eye 
[Dafna et al., 1979]. At the same time, rabbit ciliary process AC was 
localized ultrastructurally (by a cytochemical electron microscopy lo¬ 
calization technique) to the nonpigmented epithelial (NPE) cell plasma 
membranes, NPE-pigmented epithelial cell boundary, and ciliary process 
stromal capillary endothelial cells [Tsukahara and Maezawa, 1978]. 
These data suggested the presence of beta-receptors and adenyl cyclase 
together in the ciliary process (possibly NPE) epithelial membranes, 
sites which were known to be involved in the secretion of aqueous humor 
[Sears, 1980]. 
In 1980 Bromberg et al. demonstrated that beta-receptors and AC ex 
isted together in the same particulate fraction of discontinuous su¬ 
crose gradients of homogenized rabbit ciliary processes. The receptors 
125 125 
were identified by I-hydroxybenzylpindolol ( I-HYP) binding 
and characterized as beta-receptors by the ability of antagonists (tim¬ 
olol, 1-alprenolol, and d,1-propranolol) and agonists (1-norepineph- 
125 
rine, 1-isoproterenol, and phentolamine) to displace the bound I- 
HYP. Binding to the receptors was greater for timolol and other beta- 
antagonists than for beta-agonists (isoproterenol > norepinephrine), 
similar to the binding affinities documented with beta-receptors of 
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other tissues. AC was stimulated by NaF. In the same year Nathanson 
identified AC activity in rabbit, cat, dog, monkey, and human ciliary 
processes. In the rabbit, AC was stimulated by adrenergic agonists 
with a potency order: isoproterenol > epi > norepi > phenylephrine, and 
isoproterenol stimulation of AC was inhibited by propranolol and timol¬ 
ol. The data from Nathanson's and another study [Cepelik and Cernhor- 
sky, 1981] indicated that rabbit AC was stimulated by a beta -re- 
2 
ceptor. Preliminary studies suggested that human ciliary process AC 
also exhibited a beta -adrenergic receptor stimulatory pattern; this 
2 
suggestion was confirmed by a subsequent analysis [Nathanson, 1981]. 
Gregory et al. [1981a] demonstrated in rabbits that cholera toxin 
lowered IOP, decreased AHF, and increased anterior uveal blood flow 
when administered in dosages and by routes expected for endogenous medi¬ 
ators. Cholera toxin also stimulated rabbit ciliary process AC [Greg¬ 
ory et al., 1981b; Sears et al., 1981] and bound to the interdigitating 
and apical plasma membranes of the ciliary process nonpigmented epithel¬ 
ium [Mishima et al., 1982]. Subsequently it was demonstrated that for- 
skolin, a direct stimulator of AC, lowered AHF and IOP [Caprioli and 
Sears, 1983; Caprioli et al., 1984] while potently stimulating AC [Cap¬ 
rioli and Sears, 1984]. These results indicated that several agents 
lowered AHF and IOP as well as increased cAMP via receptor-mediated or 
direct stimulation. Although no ciliary process receptors specific for 
glycoprotein hormones were documented it was shown that hCG, FSH, and 
other glycoprotein hormones, known to stimulate AC by activating AC- 
coupled receptors, lowered IOP [Sears and Mead, 1983]. 
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Based upon the knowledge that stimulation of AC of the NPE plasma 
membranes resulted in decreased AHF and IOP, that cholera toxin acted 
on other epithelia to cause movement of fluid from the basal to the ap¬ 
ical portion of the cell, and that cholera toxin, forskolin, and iso¬ 
proterenol caused enlargement of the ciliary channels between the NPE 
and PE apices [Caprioli and Sears, 1984], two investigators postulated 
the manner in which AC stimulation would lead to a decrease in AHF [Cap¬ 
rioli and Sears, 1984; Sears, 1985]. The orientation of other epithel¬ 
ia on which cholera toxin is known to act is with the apical portion of 
the cell adjacent to a lumen (into which fluid is secreted when cholera 
toxin activates AC and increases cAMP). In the eye, because of invag¬ 
ination of the optic vesicle during development [Jakobiec, 1982], the 
orientation of the apical portion of the NPE cell is not adjacent to 
the lumen (i.e. the posterior chamber) but instead is adjacent to the 
pigmented epithelial cell. If cholera toxin (and other AC stimulators) 
cause movement of fluid in all epithelial cells from the base to the 
apex and thence across the apical membrane, then its effect in stim¬ 
ulating the AC of NPE cells would be movement of fluid across the a- 
pical membrane into the ciliary channel between the NPE and PE cells. 
Stimulation of AC and movement of fluid would result in the enlargement 
of the ciliary channels, a phenomenon observed when AC stimulation was 
effected by cholera toxin, forskolin, and isoproterenol [Fujita et al., 
1984]. From the ciliary channels fluid could move to the ciliary stro¬ 
ma and be reabsorbed by the stromal capillaries. The movement of fluid 
away from the posterior chamber across the NPE cell into the ciliary 
channels, with or without subsequent movement into the ciliary stroma, 
would bring about a net decrease of aqueous humor inflow. Thus the 
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authors [Caprioli and Sears, 1984; Sears, 1985] proposed the theory for 
the adenyl cyclase-receptor complex located in the ciliary NPE cell 
which would regulate aqueous humor formation and IOP. Substances able 
to stimulate the AC either via the receptor (as in the case of beta- 
adrenergic agonists, glycoprotein hormones, and cholera toxin) or di¬ 
rectly (as in the case of forskolin) would bring about a diminished AHF 
and IOP. 
The discovery of the adenyl cyclase-receptor complex of the cili¬ 
ary NPE cell and the correlation of AC stimulation with lowering of AHF 
and IOP in rabbits and man led to an exciting hypothesis for a regula¬ 
tory mechanism controlling IOP via AHF. This hypothesis provides an 
explanation for the mode of action of beta-agonists, glycoprotein hor¬ 
mones, forskolin, and cholera toxin in lowering AHF, but what about 
timolol and other beta-blockers which also lower AHF? Although timolol 
does lower IOP it has no effect on the adenyl cyclase or cAMP phospho¬ 
diesterase activity of the rabbit ciliary process tissue [Gregory et 
al., 1981b] and therefore must act via some other mechanism than this 
AHF-lowering AC-receptor complex. The mode of action of timolol and 
other beta-blockers remains to be discovered. 
G. The Adenyl Cyclase-Receptor Complex and Phosphodiesterase 
Inhibitors 
Knowing that rabbit ciliary processes contain cAMP phosphodiester¬ 
ase [Shanta et al, 1966; Sears, 1978] as well as AC and that stimula- 
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tion of AC results in lowering of IOP, the question of the effects of a 
phosphodiesterase inhibitor on this adenyl cyclase receptor complex and 
IOP has been raised. In tissues in which AC stimulation and cAMP form¬ 
ation has been established to mediate a response to drugs or hormones, 
investigators have attempted to confirm the role of cAMP by demonstrat¬ 
ing potentiation of the agent's effect by phosphodiesterase inhibitors 
[Sutherland et al., 1968; Robison et al, 1971; Poch and Reich, 1983] or 
by replication of the agent's effect by a phosphodiesterase inhibitor 
alone when the basal turnover rate of cAMP is high [Wells and Kramer, 
1981] . Phosphodiesterase inhibitors should potentiate or rep- licate 
an AC stimulator's effect by preventing the degradation of cAMP by its 
phosphodiesterase [Robison et al, 1971]. In the eye, as in other tis¬ 
sues, it is hypothesized that a phosphodiesterase inhibitor would repli¬ 
cate the effect of AC stimulators if basal production of cAMP in the 
ciliary NPE was high or at least would potentiate the effect of AC stim¬ 
ulators in the event that basal production of cAMP might be too low for 
a phosphodiesterase inhibitor alone to cause a significant increase of 
cAMP. A phosphodiesterase inhibitor alone or in combination with an AC 
stimulator would be expected therefore to cause an increase in cAMP in 
ciliary NPE cells and a resultant decrease in AHF and IOP. 
HL725 (Hoechst-Roussel Pharmaceuticals, Inc.) has been shown to be 
a potent inhibitor of cAMP phosphodiesterase [Ruppert and Weithmann, 
1982] and is believed to inhibit platelet aggregation and to cause per¬ 
ipheral vasodilation via its cAMP phosphodiesterase inhibitory action 
[Lai et al., 1981; Ruppert and Weithman, 1982; Lai et al., 1984], Iso¬ 
proterenol is known to stimulate rabbit ciliary process AC [Gregory et 
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al., 1981a; Schmitt et al., 1981] and to increase the size of ciliary 
channels [Fujita et al., 1984] and is believed to decrease IOP primar¬ 
ily by decreasing AHF [Weekers, 1955; Eakins, 1963; Bonomi, 1964b; Ross 
and Drance, 1970; Langham et al., 1971; Gaasterland et al., 1973; Taka- 
se, 1976; Mishima, 1982]. It was of interest therefore to investigate 
the effects of HL725, alone or in conjunction with low doses of isopro¬ 
terenol, on the IOP of rabbits and on the cyclic nucleotide production 
of isolated rabbit ciliary processes. 

34 
II. MATERIALS AND METHODS 
A. Rabbit IOP Experiments: 
1. Rabbit Housing Facility Environment: New Zealand male albino rab¬ 
bits weighing 2-2.5 kg. were kept in the animal care housing facility 
in individual cages with food and water available for ad lib intake. 
o 
Room temperature was 22 C. The rooms in which the animals were 
housed were maintained on a 12:12 hour light:dark schedule with wide 
spectrum fluorescent lighting in use between 6:00 a.m. and 6:00 p.m. 
controlled by an automatic timing device. Indirect light from the hall¬ 
way's fluorescent lights entered the rooms through glass-windowed doors 
between 6:00 and 7:00 p.m. Between 7:00 p.m. and 6:00 a.m. no artifi¬ 
cial overhead lights were in use in the rooms or the hallway, but be¬ 
cause the rooms were not "light tight" they were exposed to some extra¬ 
neous light (from small emergency lights in the hallway) during the per¬ 
iods of darkness of the light:dark schedule. 
Rabbits were kept in the housing facility for a minimum of one day 
and a maximum of three days before the commencement of experimental pro¬ 
cedures . 
2. IOP Measurement Procedure: Rabbits were placed individually upon 
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a table in the housing facility room and were allowed to become quiet 
and relaxed before IOP measurements were obtained. Each eye was exa¬ 
mined to determine pupil size and degree of conjunctival and perilimbal 
injection. One drop (50 microl.) of proparacaine hydrochloride (Ophthe 
tic) 0.5% solution was instilled in each eye, and the eyelids were gent 
ly retracted without applying pressure to the globe. After the rab¬ 
bit's extraocular muscles had relaxed, eyelid retraction was released 
and IOP was measured with a Digilab 30-D applanation pneumatonometer 
sensor membrane placed tangentially on the cornea until a consistent 
reading of 5 seconds duration was obtained. 
When IOP measurements were taken during the dark period of the 
light:dark schedule a small flashlight was used to locate the animal in 
its cage and to provide indirect light during the measurement period. 
3. Pneumatonometer Calibration Procedure: The Digilab 30-D applan¬ 
ation pneumatonometer was calibrated for rabbit eyes by the following 
method. Rabbits were sacrificed with 3-5 cc. of sodium pentobarbital 
(Nembutal) administered intravenously. One set of calibrations was 
obtained on eyes remaining in their orbits, and another set was obtain¬ 
ed on enucleated eyes (stabilized on saline-soaked gauze in the upper 
portion of a small beaker). Throughout the calibration procedure the 
eyes were kept moist with periodic topical applications of saline. The 
anterior chamber of each eye was cannulated by injecting a 20-gauge 
needle through the sclera (approximately 1 mm. from the corneoscleral 
limbus) using a needle gun. The needle was connected via polyethylene 
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tubing and a three-way stopcock to a saline reservoir. The reservoir 
heights were labeled with 5 mm.Hg. graduations from zero to 50 mm.Hg. 
(using the conversion of 13.5 mm.Hg./mm. saline). Beginning at 10 
mm.Hg. and progressing to 50 mm.Hg., the height of the reservoir was 
increased by increments equivalent to 5 mm.Hg. After each adjustment 
of the reservoir level to a new height the pressure in the eye was al¬ 
lowed to reach an equilibrium for five minutes. At each level of mano- 
metric pressure three tonometric pressure readings were recorded both 
with the stopcock open to the saline reservoir throughout the measure¬ 
ment procedure and with the stopcock having been closed to the saline 
column immediately before each individual tonometric measurement. Mea¬ 
surements taken with the Digilab 30-D applanation pneumatonometer were 
recorded when a consistent reading of 5 seconds duration was obtained. 
4. Documentation of Circadian Rhythm of IOP: A consistent pattern of 
IOP was noted in almost all rabbits over the course of several months 
of experimental procedures, even when the rabbits used had been in the 
housing facility as little as one day or had been exposed to light from 
a flashlight during the darkness period of the light-dark schedule. It 
was decided therefore to document the circadian rhythm present under 
those conditions. Four rabbits which had been in the housing facility 
for 2 days were utilized to determine the circadian rhythm. During the 
2 days entrainment period the rabbits were exposed to indirect light 
from a flashlight utilized during the darkness period to locate other 
rabbits and measure IOP in the room. During the following 24 hour per¬ 
iod IOP measurements were taken under the regular fluorescent lighting 
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during the 6:00 a.m. to 6:00 p.m. light period and with indirect light 
(from a flashlight placed approximately 12 inches away from the rabbit 
with the beam angled at 90 degrees from the rabbit) during the 6:00 
p.m. to 6:00 a.m. dark period. 
The IOP circadian rhythm of these four rabbits was compared to the 
IOP circadian rhythm of control eyes from HL725 intravitreal injection 
studies. Rabbits which were kept in another housing facility without a 
consistent light-dark cycle or on whom measurements were taken at signi¬ 
ficantly different times of the day were excluded from the control eyes 
circadian study group. 
5. Preparation of Solutions and Suspensions of HL725: All solutions 
and suspensions were prepared and stored at room temperature in poly¬ 
styrene test tubes. 
HL725 was supplied by Hoescht-Roussel Pharmaceutical, Inc. 
a. Solutions and Suspensions in Saline: HL725 was soluble at 
concentrations between 0.05 and 0.2%. Suspensions were placed in an 
ultrasonic bath to reduce particle size and were resuspended by swirl¬ 
ing immediately before topical applications or intravitreal injections 
were made. Fresh solutions and suspensions were prepared every two to 
three weeks although stability at room temperature for as long as three 
months was documented by systemic hypotensive effectiveness when admin¬ 
istered intravenously to rabbits whose blood pressure was monitored by 

38 
femoral artery catheterization. Sterile saline, syringes, and test 
tubes were used in preparing solutions and suspensions, and fresh solu¬ 
tions were prepared the day prior to intravitreal injections. 
HL725 0.1% and 1% suspensions had pHs ranging from 4.75 to 4.35 
and 3.6 to 3.45, respectively. pH-adjusted saline was used in control 
eyes. 
b. Suspensions in BSS and Hydroxypropylmethylcellulose: HL725 
was less soluble in BSS than in saline and at concentrations greater 
-5 
than 4-5 x 10 M formed a white flocculent precipitate. Topical sus¬ 
pensions of 1%, 2.5%, and 5% HL725 were prepared in Balanced Salt Solu¬ 
tion (BSS) with 0.5% hydroxypropylmethylcellulose (Isoptalkaline) and 
had pHs of 6.0-6.5, 4.5-5.0, and 3.0-3.5, respectively. A solution of 
0.5% hydroxypropylmethylcellulose in BSS (pH 7.0) was used as a con¬ 
trol. 
6. Other Solutions: 
a. Isoproterenol: Isoproterenol (Isuprel) 1% in buffered aqueous 
solution with preservatives was stored in its light-proof container at 
room temperature. Dilutions in saline were prepared within 30 minutes 
preceding each experiment, and exposure to light was minimized until 
topical applications were made. 
b. Ophthetic: Propracaine hydrochloride (Ophthetic) 0.5% solution. 
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pH 4.5-5.0, was utilized to obtain topical anesthesia prior to applana¬ 
tion tonometry and prior to intravitreal injections. 
7. Topical Applications: 50 microl. of HL725 solutions and suspen¬ 
sions were instilled in right eyes. 50 microl. of control solutions 
were instilled in left eyes. Isoproterenol solutions and their saline 
controls were instilled in volumes of 25 microl. in right and left 
eyes, respectively. 
8. Intravitreal Injections: Intravitreal injections of 10 microl. 
were delivered with a 50 microl. Hamilton syringe through a 30-gauge 
needle into the anesthetized, proptosed rabbit eye. HL725 solutions 
freshly prepared in sterile saline were delivered into right eyes, and 
sterile saline was delivered into left eyes. HL725 solutions and 
suspensions were prepared in concentrations appropriate to result in 
-6 -10 
final intravitreal concentrations ranging between 10 and 10 M. 
B. Rabbit Ciliary Process Cyclic Nucleotide Stimulation Experiments: 
1. Tissue Dissection Procedure: Male albino New Zealand rabbits 
weighing 2-2.5 kg. were sacrificed individually (immediately prior to 
eye dissection procedures) by intravenous injection of 3-5 cc. sodium 
pentobarbital (Nembutal). Blood was drained from the head by holding 
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the rabbit upright by the back of the neck for approximately ten sec¬ 
onds. Eyes were enucleated and placed in a beaker of cold saline (0-4 
o 
C) chilled on ice. Subsequent dissection procedures were performed 
individually on each eye. 
The eye was placed on BSS-soaked tissues on a metal bar (chilled 
with an ice-filled port) while extraneous conjunctival and extraocular 
muscle tissue was trimmed from the eye. The posterior pole of the eye 
was incised, and five incisions (through the scleral, choroidal, and 
retinal layers) were extended radially from the posterior pole to a 
point approximately 1-2 mm. anterior to the equator. The lens, zonule, 
and most of the vitreous body were freed from the anterior segment us¬ 
ing a lens loop. Retinal and choroidal tissue were removed from the 
sclera with gentle strokes with a cotton-tipped swab. The preparation 
was transferred and secured to a Plexiglas holder within a small Petri 
o 
dish. The Petri dish was filled with cold BSS (0-4 C) and placed on 
ice. Using a dissecting microscope and dissection instruments, indivi¬ 
dual ciliary processes were cut away from the ciliary body and iris. 
Ciliary processes were placed in individual 1 ml. PotterElvehjem tissue 
homogenizers full of BSS chilled on ice. 
The entire procedure was repeated until ciliary processes were har¬ 
vested from a total of four eyes. 
2. Ciliary Process Incubation Procedure: BSS was removed from each 
homogenizer to give a remaining volume of 300 microl. HL725 reagent 
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solutions and suspensions in BSS (prepared the morning of the proce- 
o 
dure) were warmed to 30 C in a water bath. Tissue homogenizers 
(containing ciliary processes in 300 microl. BSS) were placed in the 
o 
30 C water bath 5 minutes before individual reagent solutions were to 
be added. After the addition of 100 microl. of reagent solution, the 
ciliary processes and reagent solution were incubated for ten minutes. 
At ten minutes 30 microl. of TCA solution containing tritiated cAMP 
were added, and the ciliary processes were homogenized with 30-40 
strokes of a motor-driven Teflon pestle in the glass homogenizers. The 
preparation then was pelleted by centrifugation of the homogenized solu¬ 
tions at 1900-2100 x g. in an International Clinical Centrifuge. The 
supernatants were transferred into labeled test tubes and frozen at -20 
o 
C. 500 microl. of 1 N. NaOH solution were added to each pellet, and 
the mixtures were allowed to stand at room temperature for a minimum of 
three days. 
NOTE: Tissue dissection and incubation procedures later were done 
with saline in place of BSS because of HL725's lesser solubility in BSS 
than in saline. 
3. TCA Extraction Procedure, Preparation of Dilutions for RIA, and 
Determination of V : 
rp 
a. Supernatants (from procedure 2 above) were allowed to reach 
room temperature. One Pasteur pipetteful of water-saturated ether was 
added to each tube, and after vortexing the mixture most of the ether 
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layer was removed by pipetting. The ether extraction of TCA was re- 
o 
peated five times. The tubes were then warmed in a 55 C water bath 
for two hours. After the tubes were allowed to cool, the remaining 
solutions were used to prepare dilutions for the RIA and to determine 
the V of each sample. 
T 
b. Appropriate dilutions for the RIAs were prepared with acetate 
o 
buffer solution and were then frozen at -20 C until the RIAs were 
performed. 
c. The V of each tube was determined by comparing radioactivity 
T 
disintegrations per minute (determined in a 1219 Rackbeta Liquid Scin¬ 
tillation Counter) for 100 microl. volume of samples (dissolved in 1 
1/3 ml. of Ultrafluor) with d.p.m.s for 30 microl. of tritiated cAMP - 
TCA solution (combined with 70 microl. of distilled water and dissolved 
in 1 1/3 ml. of Ultrafluor). The relationship: 
Total = (conc.)x(V ) 
T 
or: 
V = {(d.p.m. for tritiated cAMP-TCA soln./d.p.m. for sample)xl00} 
T 
was used to calculate each sample's V . 
T 
d. Any solutions remaining (after the dilutions and V deter- 
o T 
minations had been made) were frozen at -20 C. 
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4. Protein Concentration Determination by Lowry Assay: This assay 
was performed in triplicate for each sample and standard solution. 
Standard protein solutions (0-60 microg. BSA/100 microl. 1 N. NaOH) 
were prepared from stock BSA solution (1.5 mg. BSA/ ml. IN. NaOH). 
The sample pellets dissolved in 1 N NaOH, which had been allowed to 
stand (in tissue homogenizers) at room temperature for a minimum of 
three days, were vortexed. 100 microl. of each standard and sample 
solution were pipetted into individual borosilicate test tubes. 1 ml. 
of a 1:1:100 1% CuSO : 2% KNatartrate: 2% Na CO solution was 
4 2 3 
added to each tube. After mixing by vortex each sample was allowed to 
stand 15-20 minutes. 100 microl. of 1 N. Phenol Reagent (Folin- 
Ciocalteau) solution were added to each tube while vortexing. After 
one hour had elapsed, 300 microl. of each sample were pipetted into 
individual wells of a titertek plate, with the first row of wells of 
the plate filled with a mixture of the three zero-standard solutions. 
Absorbance at 640 nm. was read by a Titertek Multiskan. A stand¬ 
ard curve of absorbance vs. concentration was plotted, and each sam¬ 
ple's protein concentration was determined. 
5. Determination of Cyclic Nucleotide Concentration by cAMP and cGMP 
RIAs: Biomedical Technologies Inc. cyclic nucleotide RIA kits were 
utilized. Duplicates of standards and samples were used. The previous¬ 
ly prepared and frozen sample dilutions as well as the RIA kit solu¬ 
tions were allowed to warm to room temperature. Cyclic nucleotide stan¬ 
dard solutions (5-500 fM/100 microl.) were prepared. Both the standard 
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and sample solutions were acetylated with 5 microl. of freshly prepared 
acetic anhydride:triethylamine 1:2 mixture. 100 microl. of tracer solu¬ 
tion were added to each tube. 100 microl. of antiserum were added to 
all but the first two tubes, to which nonspecific binding reagent was 
added. The racks of tubes were swirled gently for 60 seconds, covered 
o 
with foil, and incubated at 4 C for 18-20 hours. 
After 18-20 hours incubation all tubes then were placed on ice, 
and 1 ml. acetate buffer was added to each tube. The tubes were centri- 
o 
fuged at 5000 r.p.m. for 15 minutes at 0-4 C in a Sorvall RC5B Refri¬ 
gerated Superspeed Centrifuge. The supernatants were removed by pipett 
ing. Each pellet was counted for one minute in a Searle Analytic Inc. 
Model 1190 Automatic Gamma System. 
The standard curve of percent binding vs. cyclic nucleotide concen¬ 
tration was plotted, and the cyclic nucleotide concentration of each 
sample was determined from its percent binding. Final cyclic nucleo¬ 
tide concentration (in pM. cyclic nucleotide/ mg. protein) was calcu¬ 
lated by taking into account each sample's acetate buffer dilution, 
V , and protein concentration, as well as the tritiated cAMP added. 
T 
C. Data Analysis: Linear regression analyses, statistical calcula¬ 





A. Rabbit IOP Experiments: 
1. Pneumatonometer Calibration for Rabbit Eyes: 
All calibration data exhibited linear relationships between pneuma¬ 
tonometer IOPs and manometer IOPs. Linear regression analysis was per¬ 
formed on tonometer versus manometer IOP for each rabbit to determine 
the slope and standard error of estimate of each line. Mean slope + 
SEM was calculated for each calibration condition (eyes in orbits: open 
or closed stopcock; enucleated eyes: open or closed stopcock). The 
mean slopes of the pneumatonometer calibration curves for rabbit eyes 
in their orbits were (mean + SEM, n=5) 0.83 + 0.01 and 0.98 + 0.02 un¬ 
der conditions of open and closed stopcocks, respectively. The mean 
slopes of the calibration curves for enucleated rabbit eyes were 0.82 + 
0.02 and 1.04 + 0.02 with open and closed stopcocks, respectively. All 
curves had y-intercepts equal to 0. 
To simplify the representation of pneumatonometer calibration 
curves, they were drawn by linear regression analysis of mean tonometer 
IOPs and manometer IOPs for pooled data for each calibration condition. 
(See figures 1-4.) These curves had slopes (eyes in orbits: open 
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stopcock: 0.83 +_ 0.01 and closed stopcock: 0.98 +_ 0.03; enucleated 
eyes: open stopcock: 0.82 + 0.03 and closed stopcock: 1.04 +_ 0.03) sim¬ 
ilar to the mean slopes and SEMs calculated from calibration curves of 
individual eyes. 
Pooled variances and the t-statistic for comparison of two slopes 
were calculated to determine the statistical significance of the dif¬ 
ferences between slopes of the calibration curves obtained under dif¬ 
ferent conditions. The difference between mean slopes of lines obtain¬ 
ed with open stopcocks in comparison to those obtained with closed stop¬ 
cocks was significant at p< 0.001 for both enucleated eyes and eyes in 
their orbits. In contrast, the difference between mean slopes of lines 
obtained with enucleated eyes in comparison to those obtained with eyes 
in their orbits was statistically insignificant under both open and 
closed stopcock conditions. The t-statistic for comparison of mean 
slopes to the constant 1.0 revealed that the mean slopes of lines ob¬ 
tained with open stopcocks were significantly (p<0.01) different from 
1.0 but that the mean slopes of lines obtained with closed stopcocks 
were not significantly different from 1.0. 

47 





Figure 1: Mean Pneumatonometer IOPe vb. Manometer IOP for rabbit eyes 
in their orbits (n=5). Calibration data were obtained under open 





















Figure 2: Mean Pneumatonometer lOPs vs. Manometer IOP for rabbit eyes 
in their orbits (nc5). Calibration data were obtained under closed 
stopcock conditions. Slope = 0.98 0.03. 
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Figure 3: Mean Pneumatonometer IOPs vs. Manometer IOP for enucleated 
rabbit eyes (n=5). Calibration data were obtained under open stopcock 
conditions. Slope = 0.82 +. 0.03. 





Figure 4: Mean Pneumatonometer IOPs vs. Manometer IOP for enucleated 
rabbit eyes (n=5). Calibration data were obtained under closed stopcock 
conditions. Slope = 1.04 + 0.03. 
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2. IOP Circadian Rhythm : 
{Note: Circadian Time: 0 C.T. = 6:00 a.m.= lights on, and 12 C.T. = 
6:00 p.m.= lights out) 
See figures 5 and 6 for graphs of the IOP circadian rhythms of 
circadian study eyes and the HL725 study control eyes. Figure 7 pre¬ 
sents both circadian rhythms on the same graph. 
The four rabbits which had been in the animal care facility 2 days 
prior to the commencement of the circadian study demonstrated an IOP 
circadian rhythm similar to that previously observed in all rabbits 
(kept in the same environment) which had been used for the HL725 stud¬ 
ies. IOP fell during the morning and rose in the afternoon and early 
evening. At one hour circadian time the first IOP reading was taken, 
and at 25 hours (or one hour circadian time the next day) the final IOP 
measurement was obtained. IOP at one hour circadian time (CT) on day 1 
and day 2 was 20.5 + 0.4 mm.Hg. and 19.6 + 0.3 mm.Hg., respectively. 
Between one and two hours CT the IOP rapidly fell to 16.3 + 0.4 mm.Hg. 
and remained near 16 mm.Hg. until five hours CT. Between five and six 
hours CT, IOP began a rapid rise to a small peak, 20.9 + 0.5 mm.Hg., at 
nine hours CT and then to the higher recorded peak, 23.6 + 0.4 mm.Hg., 
at thirteen hours CT. Two IOP measurements were taken during the dark 
period of the light-dark cycle, at 13 and 17 hours CT. 
In this study the minimum IOP, 16.3 + 0.4 mm.Hg., occurred at two 
hours CT, and the maximum IOP, 23.6 _+ 0.4 mm.Hg., occurred at 13 hours 
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CT. The amplitude of the curve between minimum and maximum IOP was 7.4 
+ 0.8 mm.Hg. 
The circadian rhythm of the control (L) eyes (of HL725 intravit- 
real injection studies) exhibited an IOP fall in the morning and a rise 
in the afternoon and early evening. IOP at one hour CT on day 1 and 
day 2 was 20.2 + 0.5 mm.Hg. and 18.9 + 0.5 mm.Hg., respectively. Be¬ 
tween one and two hours CT the IOP rapidly fell to 17.3 + 0.5 mm.Hg and 
remained near 17 mm.Hg. until five hours CT. Between five and six 
hours CT, IOP began a rapid rise to a single maximal peak, 22.9 + 0.4 
mm.Hg., at 13 hours CT. Only one IOP measurement was taken during the 
dark period of the light-dark cycle, at 13 hours CT. 
In this group of rabbits the minimum IOP, 17.3 +_ 0.5 mm.Hg., occur¬ 
red at two hours CT, and the maximum IOP, 22.9 +0.4 mm.Hg, occurred at 
13 hours CT. The amplitude of the curve between minimum and maximum 








Figure 5: IOP vs. Circadian Time for rabbits after 2 days entrainment 
to 12 hours light: 12 hours dark. Values represent IOP mean of 8 eyes 
(n=4) + SEM. 
rtflh IOP 
O- 
Fiqure 6: IOP vs. Circadian Time for rabbits after one day to several 
weeks entrainment to 12 hours light: 12 hours dark. Values represent 
IOP mean of 27 control eyes (from HL725 intravitreal injection studies) 
IOP CIRCPDIflh (WYTVM: CONTROL EYES N*Z7 












Figure 7: IOP vs. Circadian Time. A comparison of IOP circadian 
rhythms of circadian study eyes and of HL725 studies control eyes. 
Values for circadian study eyes represent IOP mean of 8 eyes (n=4) + 




3. Topical Applications of HL725: 
a. 0.1% Solutions and 1% Suspensions in Saline: 
Topical application of HL725 0.1% solution (in saline) resulted 
in a modest, short-term decrease in IOP in the treated eye in compari¬ 
son to the control eye. The difference in IOP of the treated eye com¬ 
pared to the contralateral control eye (delta (R-L) IOP) at 3 hours was 
-1.4 mm.Hg. and at four hours was -0.8 mm.Hg. (p<0.05, n=8). See fig¬ 
ures 8 and 9. 
Topical application of HL725 1% suspension (in saline) caused in¬ 
jection of conjunctival and perilimbal vessels of four hours duration 
with an accompanying bilateral transient hypertension (documented at 
one hour) and followed by unilateral longer-term hypotension. Delta 
IOP at 3 hours was -2.3 mm.Hg., at 4 hours -4.0 mm.Hg., and at 8 hours 
-1.5 mm.Hg. (p<0.05, n=4). See figures 10 and 11. 
b. l%-5% Suspensions in BSS/HPMC: 
Topical application of HL725 1% suspension in BSS/HPMC resulted 
in a modest, short-term decrease in IOP with delta IOP at 1 hour -1.4 
mm.Hg. and at 2 hours -0.8 mm.Hg. (p<0.05, n=8). (See figures 12 and 
13.) Topical application of HL725 2.5% suspension in BSS/HPMC caused 
no significant changes in IOP. (See figure 14.) Topical application 
of HL725 5% suspension in BSS/HPMC resulted in modest decreases in IOP 
in the treated eye, with a delta IOP of -1.5 mm.Hg. at 12 hours 
(p<0.05, n=4). (See figures 15 and 16.) 
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TOPICAL rt.725 : 0.1* SOLUTION IN SALIft 
Figure 8: IOP vs. Time for eyes treated with topical applications of 
HL725 0.1% solution (in 6aline) OD and of pH-matched saline OS. Values 
represent IOP means of right and left eyes (n=8). "Significant at 
p<0.05 by paired t-test (two-tailed). 
TOPICAL H.7Z5 0.1*: DELTA (R-L) IOP VS. Tift 
Figure 9: Delta (R-L) IOP vs. Time for eyes treated with topical 
applications of HL725 0.1% solution (in saline) OD and of pH-matched 
saline OS. Values represent delta IOP means +SEMs (n=8). "Significant 
at p<0.05 by two-tailed t-test. 
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Figure 10: IOP vs. Time for eyes treated with topical applications of 
HL725 1% suspension (in saline) OD and of pH-matched 6aline OS. Values 
represent IOP means of right and left eyes (n=4). ‘Significant at 
p<0.05 by paired t-test (two-tailed) . 
TOPICAL PL725 IX: DELTA (R-L) IOP VS. Tift 
deltalOP 
O- 
Figure 11: Delta (R-L) IOP vs. Time for eyes treated with topical 
applications of HL725 1% suspension (in 6aline) OD and of pH-matched 
saline OS. Values represent delta IOP means +_ SEMs (n=4). 
•Significant at p<0.05 by two-tailed t-test. 
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Figure 12: IOP vs. Time for eyes treated with topical applications of 
HL725 1% suspension (in BSS/HPMC) OD and of saline OS. Values 
represent IOP means of right and left eyes (nc8). ‘Significant at 
p<0.05 by paired t-test (two-tailed). 
TOPICAL rt.725 IX (BSS/FfTC): DELTA (R-L) IOP VS. Tift 
Figure 13: Delta (R-L) IOP vs. Time for eyes treated with topical 
applications of HL725 1% suspension (in BSS/HPMC) OD and of saline OS. 
Values represent delta IOP means ♦ SEMs (n=8). ‘Significant at p<0.05 
by two-tailed t-test. 
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TOPICflL H.725: E.5* SUSPENSION IN BSS^IC 
Figure 14: IOP vs Time for eyes treated with topical applications of 
HL725 2.5% suspension (in BSS/HPMC) OD and of saline OS. Values 








TOPICAL H.725: 5>. SUSPEhEION IN BSS/hPMC 
Figure 15: IOP vs. Time for eyes treated with topical applications of 
HL725 5% suspension (in BSS/HPMC) OD and of saline OS. Values 
represent IOP means of right and left eyes (n=4). 'Significant at 
p<0.05 by paired t-test (two-tailed). 
TOPICAL (-L7Z5 5X (BSS/VfMC): DELTA (R-L) IOP VS. TINE 
Figure lb: Delta (R-L) IOP vs. Time for eyes treated with topical 
applications of HL725 5% suspension (in BSS/HPMC) OD and of saline OS. 
Values represent delta IOP means *_ SEMs (n=4 ). 'Significant at pCO.OS 
by two-tailed t-test. 
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4. Intravitreal Injections of HL725: 
-6 
Intravitreal injections of HL725 in concentrations between 10 % 
and 10% (giving calculated final intravitreal concentrations between 
-10 -3 
10 M and 10 M) effected no significant change in IOP of the 
study eyes in comparison to the IOP of the contralateral control eyes 












Figure 17: iop vs. Time for eyes treated with intravitreal injections of 
HL725 10-6% (final intravitreal concentration of 10-10 M) OD and of 
saline OS. (n=S) 








Figure 18: IOP vs. Time for eyes treated with intravitreal injection of 
HL725 10-5 % (final intravitreal concentration of 10-9 M) OD and of 












Figure 19: IOP vs. Time for eyes treated with intravitreal injections 
of HL725 10-4% (final intravitreal concentration of 10-8 M) OD and of 
saline OS. (n=5) 





Figure 20: IOP vs. Time for eyes treated with intravitreal injections 
of HL725 10-3% (final intravitreal concentration of 10-7 M) OD and of 
saline OS. (n=5) 
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Figure 21: IOP vs. Time for eyes treated with intravitreal injections 
of HL725 10-2% (final intravitreal concentration of 10-6 M) OD and of 
saline OS. (n = 5) 





Figure 22: IOP vs. Time for eyes treated with intravitreal injections 
of HL725 10-1% (final intravitreal concentration of 10-5 M) OD and of 
saline OS. (n=5) 
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Figure 23: IOP vs. Time for eyes treated with intravitreal injections 
of HL72S 1% (final intravitreal concentration of 10-4 M) OD and of 
saline OS. (n=5) 
IKTRPVITREPL INJECTION OF 4.725 18* 
Figure 24: IOP vs. Time for eyes treated with intravitreal injections 
of HL725 10% (final intravitreal concentration of 10-3 M) OD and of 
saline OS. (n=2) 
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5. Topical Isoproterenol: 
Topical applications of isoproterenol in concentrations ranging 
from 0.01% to 1.0% resulted in IOP decreases in the treated eye ranging 
from -3.4 to -5.0 mm.Hg. at 1 hour to 0 to -0.6 mm.Hg. at 12 hours. 
Effects of various concentrations of topical isoproterenol are repre¬ 
sented by plots of (a) delta IOP (mean, n=5) vs. time for each concen¬ 
tration of isoproterenol and (b) [delta IOP x time] (area under the 
curve calculated for each delta IOP vs. time curve or IOP hours) vs. 
[log(concentration of isoproterenol)]. See figures 25 and 26. 
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Figure 25: Delta (R-L) IOP vs. Time for topical applications of 
isoproterenol ranging in concentration between 0.01 and 1%. Values 
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Ficrure 26: [Delta IOP x Time] vs. [Log(Conc.)J for topical 
applications of isoproterenol ranging in concentration between 0.01 and 
1%. Values represent areas (under the curves) calculated from the 
curves of delta IOP vs. time for each concentration of isoproterenol. 
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6. Synergism Between HL725 and Isoproterenol: 
a. Topical Isoproterenol 0.01% 01) + Intravitreal HL725 OP: 
Intravitreal injection of HL725 0.01% (final intravitreal concen- 
-6 
tration of 10 M) in the right eye (in comparison to intravitreal in¬ 
jection of saline in the left eye) resulted in modest potentiation of 
isoproterenol's hypotensive effect, with delta (R-L) IOP of -1.5 mm.Hg. 
at 4 and 6 hours (p<0.05, n=6). See figures 27 and 28. 
Intravitreal injection of HL725 0.1% (final intravitreal concen- 
-5 
tration of 10 M) OD resulted in modest potentiation (longer term 
than that of 0.01% HL725) of isoproterenol's hypotensive effect. Delta 
IOP was -1.5, -2.2, and -1.0 mm.Hg. at 6, 10, and 12 hours, respective¬ 
ly (p<0.05, n=6). See figures 29 and 30. 
b. Topical Isoproterenol 0.1% OU + Intravitreal HL725 OD: 
Intravitreal injection of HL725 0.1% (final intravitreal concen- 
-5 
tration of 10 M) OD (incomparison to saline OS) appeared to cause a 
modest potentiation of isoproterenol's hypotensive effect, although 
with n=3 none of the differences of right and left IOP (delta IOPs) 
were statistically significant. See figure 31. 
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TOPICAL ISOFROTDENOL 0.01X OU ♦ INTRAVITREAL H.7Z5 0.017 00 
Figure 27: IOP vs. Time for topical applications of isoproterenol 
0.01% OU plus intravitreal injection of HL725 0.01% (final intravitreal 
-6 
concentration of 10 M) OD and of saline OS. Values represent mean 
IOPs (n=6). ‘Significant at p<0.05 by paired t-test (two-tailed). 
TOPICAL ISOPROTERENOL 0.01* 0U ♦ INTRAVITREAL H.725 0.017. 0D 
DELTA (fH_) I0P VS. TINE 
Figure 2B: Delta (R-L) IOP vs. Time for topical applications of 
isoproterenol 0.01% OU plus intravitreal injection of HL725 0.01% 
-6 
(final intravitreal concentration of 10 M) OD and of saline OS. 
Values represent mean delta IOPs + SEMs (n=6). ‘Significant at p<0.05 
by two-tailed t-test. 
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TOP I COL ISOPROTERENOL 8.01'/. OU * INTRPVITREPL HL725 0.1'/. 00 
Figure 29: IOP vs. Time for topical applications of isoproterenol 
0.01% OU plus intravitreal injections of HL725 0.1% (final intravitreal 
-5 
concentration of 10 M) OD and of saline OS. Values represent mean 
IOP (n=6). ‘Significant at p<0.05 by paired t-test (two-tailed). 
TOPICAL ISOPROTERENOL 0.01* 0U ♦ INTW/ITREPL H.725 B.1X 00 
DELTA (R-L) IOP va. TIfC 
Figure 30: Delta (R-L) IOP vs. Time for topical applications of 
isoproterenol 0.01% OU plus intravitreal injections of HL725 0.1% 
-5 
(final intravitreal concentration of 10 M) OD and of saline OS. 
Values represent mean delta IOPs + SEMs (n=6). ‘Significant at p<0.05 
by two-tailed t-test. 
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TOPICAL ISOPROTERENOL 0.1*/. OU ♦ INTRAVITREAL 4.725 0.15c OD 
Figure 31: IOP vs. Time for topical applications of isoproterenol 0.1% 
OU plus intravitreal injections of HL725 0.1% (final intravitreal 
-5 




B. Rabbit Ciliary Process Cyclic Nucleotide Stimulation: 
1. Ciliary Process cAMP Stimulation: 
Ciliary process cAMP stimulation was greater in the presence than 
-7 
in the absence of HL725 at all concentrations of HL725 between 10 
-3 
and 10 M. Stimulation of cAMP (cAMP level in the presence of HL725/ 
-4 
basal cAMP level) was greatest at HL725 10 M. concentration. See 
figure 32. 
2. Ciliary Process cGMP Stimulation: 
Under the procedure conditions, preliminary studies of ciliary pro¬ 
cess cGMP stimulation found no detectable cGMP in the absence of 
HL725. Ciliary process cGMP was detectable at all concentrations of 
-7 -3 
HL725 between 10 and 10 M. See figure 33. 
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CILIARY PROCESS cflMP PRODUCTION: STIMULATION BY K.725 
CONCENTRATION OF H.725 (H) 
Figure 32: Ciliary Process cAMP Production: Stimulation of cAMP vs. 
Concentration (M) of RL725. Stimulation of cAMP equals cAMP 
(concentration at respective HL72S concentration)/ cAMP (concentration 
at zero M. HL725) or cAMP production/basal CAMP. Values represent 
means + SEMs for n=6. 
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CILIARY PROCESS cSK5 PRODUCTION: STIMULATION BY H.7Z5 
CONCENTRATION OF ML725 (M) 
Figure 33: Ciliary Process cGHP Production: Stimulation by HL725. 
Production of cGMP (pM. cGMP/mg. protein) vs. Concentration (M) of 





A. Pneumatonometer Calibration for Rabbit Eyes: 
The applanation pneumatonometer consists of a floating tip sensor 
on a piston with a frictionless pneumatic bearing which allows the sen¬ 
sor to float on a cushion of gas (supplied by a compressed gas source) 
[Walker & Langham, 1975]. Application of the tonometer tangential to 
the cornea results in a displacement of the sensor membrane, an in¬ 
crease in the gas pressure, subsequent flattening of the corneal sur¬ 
face, and an inward spreading of the flattening across the corneal 
layers until the inward-acting force (F , pneumatic force) is bal- 
1 
anced by the outward-acting force (F , intraocular force) [Durham et 
2 
al., 1965]. The sensor is designed such that the force applied to the 
diaphragm from the gas pressure in the chamber (F ) is equal to the 
1 
force applied to the diaphragm by the pressure of the eye (F ) and 
2 
such that the sensor measures IOP when the outer coats of the eye are 
flattened (applanated) by contact. Pneumatic applanation tonometry is 
described by a function relating sensor P (P ) to IOP (P ): 
1 2 
2 
2Rt/A = (P /P XlnlK) + (l-iK), 
1 2 
where: R = corneal radius of curvature; 




A = jet tube radius; 
P /P = ratio of sensor pressure (P ) to IOP (P ); and 
12 12 
T = factor dependent on geometric relationship of cornea and sensor 
during applanation (affected by pressure ratio and probe geometry). 
Rearranging the above function: 
2 
P = {[2Rt/A - (1- f )](P )}/ln Y , 
1 2 
one can see that the measured intraocular pressure detected by the sen¬ 
sor (P ) is dependent not only on the actual intraocular pressure and 
1 
probe geometry but also on corneal radius of curvature (R) and other 
corneal properties (e.g.: thickness) affecting the deflection (t) of 
the cornea from the sensor edge during applanation. The slope of a 
graph of measured IOP (sensor or tonometer pressure, P ) versus ac- 
1 
tual IOP (P ) would reflect the corneal properties (radius of curva- 
2 
ture and thickness) as well as probe geometry and tube radius. 
The Digilab 30-D applanation pneumatonometer has been calibrated 
for the human eye, whose anterior corneal surface has a normal average 
radius of curvature equal to 7.8 mm. [Newell, 1982]. Because the appla¬ 
nation pneumatonometer was used to determine IOP of rabbits, whose cor¬ 
neal radius of curvature is dependent on size and age and has a normal 
average variously reported between 7.0 and 8.25 mm. [Prince, 1964], it 
was necessary to calibrate the pneumatonometer for rabbits similar in 
size to those used in the later studies. 
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The calibration curves for rabbit eyes demonstrated a direct rela¬ 
tionship between measured IOP (P ) and actual IOP (P ), with mean 
1 2 
slopes of calibration curves under closed stopcock conditions not signi¬ 
ficantly different from 1.0. It is apparent from these calibration da¬ 
ta that the corneal properties of these rabbit eyes under normal condi¬ 
tions did not result in a relationship between P and P different 
1 2 
from that found by calibration of the tonometer for human eyes. 
In the calibration procedure with the stopcock open, any fluid dis¬ 
placed by corneal displacement during applanation tonometry would flow 
through the cannula back towards the reservoir, preventing any increase 
in IOP and therefore maintaining the IOP at the set manometric level. 
With the stopcock closed the conditions of the normal eye are reproduc¬ 
ed, and any corneal indentation results initially in a slightly higher 
IOP (as intraocular fluid displacement causes increased IOP) and later 
in a slightly lower IOP (as pneumatonometer force causes egress of in¬ 
traocular fluid through the outflow channels) [Durham et al., 1965; 
Langham & McCarthy, 1968]. Theoretically applanation tonometry, unlike 
indentation tonometry, causes minimal displacement of the cornea and 
intraocular fluid and therefore only small changes in IOP [Durham et 
al., 1964; Langham & McCarthy, 1968], If corneal indentation is small 
enough the pressure measurement should be independent of ocular rigidi¬ 
ty and the pressure-volume relationship of the eye [Langham & McCarthy, 
1968] . 
Early studies of applanation pneumatonometry indicated that the 
IOP measurement could be taken before IOP was altered by any corneal 
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indentation or applanation pressure and that a close correlation be¬ 
tween tonometric and manometric IOPs could be obtained under open and 
closed stopcock conditions [Durham et al., 1965]. With a rigid sensor 
tip (without pneumatic bearing) the pressure difference between closed 
and open stopcock procedures was 1 mm.Hg. at an IOP of 15 mm.Hg. and 2 
mm.Hg. at an IOP of 20 mm.Hg. (with corresponding volume displacements 
of 2.2 j<\. and 0.8 fl., respectively) [Langham & McCarthy, 1968]. With 
an air-bearing floating tip the pneumatic force (approximately 2 g.) 
causes an additional pressure difference of 1-2 mm.Hg. [Walker & Lang¬ 
ham, 1975]. If the tonometer is acting as a true applanating system, 
corneal indentation and IOP change .should be small enough that IOP 
measurements under open and closed stopcock conditions should be equal 
[Langham & McCarthy, 1968]. 
In these calibration experiments there was a significant differ¬ 
ence in the slopes obtained with open and closed stopcocks. These 
results suggested that the applanation tonometer was not a true appla¬ 
nating system and was causing a detectable (though small) amount of 
corneal indentation. In this case it would be important to convert to¬ 
nometer reading to actual IOP (manometer pressure) using the calibra¬ 
tion curve for conditions analagous to the normal eye (i.e.: closed 
stopcock), but because the slope of this curve, 0.98 + 0.02, was not 
significantly different from 1.0 it was unnecessary to convert the re¬ 
corded IOP measurements to a value corrected for the rabbit eyes. 
Based upon the observation that the pneumatic tonometer caused in¬ 
dentation significant enough to result in a difference between closed 
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and open stopcock measurements, one would suspect that the pressure 
measurements would not be completely independent of ocular rigidity and 
the pressure-volume relationship of the eye. Although the measurements 
would give no direct estimate of ocular rigidity [Sears, 1966] they 
would be affected by the ocular rigidities of the eyes. Differences in 
odular rigidity (caused by post-mortem changes as well as differences 
already existent in vivo) could result in different calibration 
curves. In this case no difference was observed between calibration 
curves of enucleated eyes and eyes in their orbits used within a few 
hours post-mortem. 
B. TOP Circadian Rhythm: 
The rabbits used in these studies were not kept in as well-control 
led an environment or entrained as long as the rabbits of the two pre¬ 
viously reported reproducible rabbit IOP circadian rhythm models. 
Nevertheless, they exhibited a remarkably consistent IOP circadian 
rhythm. Rabbits entrained to the light:dark cycle for only two days ex 
hibited a circadian rhythm similar to that of rabbits kept in the same 
environment between 1 day and several weeks. Entrainment of a circadi¬ 
an rhythm or resetting/phase-shifting of a circadian pacemaker can be 
effected by as little as one brief exposure to light during a receptive 
period of the phase-response curve, but entrainment or resetting of a 
circadian pacemaker can require as much as several days to weeks expo¬ 
sure to a new light:dark cycle [Moore-Ede et al., 1982 & 1983]. The 
rabbits used in this series of experiments may have been kept in an en- 
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vironment with a similar light:dark environment prior to their delivery 
at Yale or may have required merely brief exposure to the light/dark 
cycle in the new environment for entrainment of the IOP circadian 
rhythm. 
The similarity between the two curves, representing the IOP circa¬ 
dian rhythms of (1) a group of rabbits used specifically to document 
the IOP circadian pattern and of (2) several rabbits used for HL725 
studies over the course of several months, suggests that the possible 
variation in the rabbits' environment (exposure to small amounts of 
light during dark periods, changes in social cues by different investi¬ 
gators entering the rooms at different times on different days, and 
other possible changes which might occur in a communal housing facili¬ 
ty) were not significant enough to cause obvious changes in the rab¬ 
bits' IOP rhythm.. The light:dark cycle cue and perhaps the social cues 
of animal care facility workers arriving and leaving the area at the 
same time each day were consistent enough to maintain a reproducible 
IOP rhythm. The small amount of light to which the rabbits were ex¬ 
posed during the early portion of the dark period would have been ex¬ 
pected to cause a phase delay in the circadian rhythm [Moore-Ede et 
al., 1982& 1983] if any effect at all. The light exposure may have 
caused no effect because its intensity and duration were insufficient 
to change the circadian rhythm, because it fell during a time of insta¬ 
bility on the phase-response curve [Moore-Ede, 1982], or because other 
environmental cues (e.g.: social cues of workers arrival and departure 




The rabbit IOP circadian rhythm in this series of studies was sim¬ 
ilar to the circadian rhythms of the rabbit models of Rowland et al. 
[1981] and Gregory et al. [1985], although the shape and amplitude of 
the curve differed in some respects. In comparison to the rabbit IOP 
pattern of Rowland et al [1981] and of Gregory et al. [1985], the cir¬ 
cadian curve had a smaller amplitude (6-7.4 mm.Hg. versus 12-13 mm.Hg. 
and 7.4-8.5 mm.Hg.). In this study measurements were taken less fre¬ 
quently during the dark period, and it is possible that a larger ampli¬ 
tude might have been seen if an additional reading had been taken be¬ 
tween 12 and 16 hours circadian time. The small amount of light enter¬ 
ing the animal rooms from emergency lighting in the hallways might have 
caused a diminished IOP amplitude by decreasing the difference between 
light and dark intensity. A greater intensity of overhead illumination 
or a dawn and dusk transition of illumination [Moore-Ede et al, 1982] 
might result in a larger amplitude of IOP change. 
Despite the minor differences between the IOP pattern and that of 
the other two models, in the environment described the rabbits exhibi¬ 
ted a reproducible IOP circadian rhythm with IOP lower during the light 
period and higher during the dark period. Rabbits in this environment 
could be used to study the effects of various agents on IOP during dif¬ 
ferent periods of the circadian rhythm and the mechanisms effecting the 
IOP circadian pattern. To alleviate any possible changes of the rhythm 
by light exposure during the dark period and to facilitate more fre¬ 
quent IOP measurement in the dark, a long-wavelength red light could be 
employed during reading in the dark phase of the cycle. 

80 
Of what importance is the circadian rhythm in ophthalmologic re¬ 
search? Almost all physiologic variables exhibit circadian rhythms, 
and any investigation of mechanisms controlling or drugs affecting a 
physiologic variable must take into consideration the possible effects 
of circadian variation in that variable and other systemic variables. 
The circadian system is believed to consist of central pacemakers or 
primary oscillators, secondary oscillators as well as passive elements 
in peripheral tissues, transducers or receptors which transform environ¬ 
mental into biologic cues, and mediators which transmit temporal infor¬ 
mation between transducers, primary oscillators, secondary oscillators, 
and passive elements. All portions of this system need be considered 
in an analysis of circadian rhythms. Circadian rhythmicity appears to 
occur at all physiologic levels, with plasma and anterior chamber vol¬ 
ume [Mapstone & Clark, 1985], plasma hormone level, receptor number and 
affinity [Titanchi et al., 1984], intracellular enzyme inducibility 
[Moore-Ede et al, 1982], and even cellular content of cAMP and cGMP 
[Murakami & Takahashi, 1983; Schwarz et al., 1984] and guanyl cyclase 
activity [Cannela & Vesely, 1984] exhibiting circadian rhythms. Drug 
effectiveness and toxicity is affected by circadian rhythms of drug 
absorption, metabolism, excretion, plasma protein binding, and plasma 
dilution degree, and by circadian variation of tissue susceptibility 
[Moore-Ede et al., 1982]. 
Circadian variations of mediator secretion and tissue susceptibil¬ 
ity may be some of the more important factors of pharmacologic effect¬ 
iveness. In the example of systemic hypertension, beta-blockers are 
known to be effective treatment, but during the period between 0600 and 
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1000 hrs. when the most rapid rise of arterial blood pressure occurs 
beta-blockers appear not to lower blood pressure possibly because of an 
increase in sympathetic activity and alpha-adrenergically mediated per¬ 
ipheral arteriolar constriction [Raftery & Carrageta, 1985] on which 
beta-blockers would have no effect. The differences of effectiveness 
of epinephrine, timolol, and acetazolamide in changing aqueous humor 
formation at different circadian times may be caused by circadian 
rhythms of tissue susceptibility at the receptor or intracellular level 
or of endogenous hormone secretion. The mechanism controlling IOP cir¬ 
cadian changes may be adrenergically mediated [Gregory et al., 1985], 
and one possible mechanism controlling IOP may involve an adenyl cyc¬ 
lase-receptor complex. The effects of alpha- and beta-adrenergic 
agents may be different at different circadian times because of cir¬ 
cadian rhythms of plasma hormone and catecholamine levels and of tissue 
susceptibility (including receptor level and affinity, intracellular 
enzyme inducibility, cellular content of cyclic nucleotides, and other 
factors). Obviously it will be important in the future to investigate 
the circadian rhythms of physiologic, pharmacologic, and biochemical 
properties of the eye as well as the oscillator, transducer, and medi¬ 
ator components of the circadian system in order to elucidate the mech¬ 
anisms controlling IOP. Preliminary studies are being performed on 
rabbit models prior to human investigations. 
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C. Intracellular Messengers, a Phosphodiesterase Inhibitor, and TOP: 
Following the discovery of cAMP [Cook et al., 1957; Sutherland & 
Rail, 1957] and the report of its action as the intracellular mediator 
of epinephrine's and glucagon's glycogenolytic effect in the liver 
[Sutherland & Rail, 1960], adenyl cyclase and cAMP were found in all 
animal species and all tissues [Perkins, 1973] and cAMP was shown to be 
the intracellular mediator of the effects of a variety of hormones on a 
variety of tissues [Sutherland et al., 1968; Butcher et al., 1970; Jost 
& Rickenberg, 1971; Rail, 1982]. cAMP was designated the ubiquitous 
second messenger, and a simple model of the cAMP-mediated system was 
characterized by the series of events in which a hormone (first messeng¬ 
er) stimulated adenyl cyclase to catalyze the conversion of ATP to cAMP 
(second messenger) which then caused a physiologic response by activa¬ 
tion of protein kinases [Walsh et al., 1968; Krebs & Preiss, 1975; 
Beavo & Mumby, 1982]. The intracellular message was terminated by 
degradation of cAMP to 5'-AMP by phosphodiesterase [Sutherland et al., 
1968]. 
Since the proposal of the model of the second messenger system, 
theories of hormonal regulation and models of intracellular metabolism 
have become increasingly complex with the discovery of other cyclic 
nucleotides and intracellular messengers and of other regulatory pro¬ 
teins and enzymes. The model is not yet complete and the role of many 
of the components of the model is not clear, but the picture includes 
stimulatory and inhibitory membrane receptors, stimulatory and inhibi¬ 
tory guanine nucleotide binding proteins, adenyl and guanyl cyclases 
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(membrane-associated and cytosolic), multiple forms of cyclic nucleo¬ 
tide phosphodiesterases (membrane-associated and cytosolic), calmodulin 
2+ 2+ 2+ 
and other regulatory proteins and ions (Ca , Mg , Mn , and 
+ 
Na ). 
The plasma membrane contains (or has associated with it) three pro¬ 
tein components of the adenyl cyclase-receptor system: receptors, nu¬ 
cleotide regulatory proteins, and catalytic components of adenyl cy¬ 
clase. Stimulatory and inhibitory receptors are coupled to adenyl cy¬ 
clase. Stimulatory receptors (R ) include beta-adrenergic [Hekman et 
s 
al., 1984; Caron et al., 1985], adenosine (A ) [Daly, 1985], dopamine 
2 
(D ) [Cote et al., 1985], LH and other hormones [Ross & Gilman, 
1 
1980]. Inhibitory receptors (R ) include alpha -adrenergic [Lef- 
i 2 
kowitz et al., 1984; Caron et al., 1985; Mitrius & U'Prichard, 1985], 
adenosine (A ) [Daly, 1985; Phillis & Barraco, 1985], muscarinic chol- 
1 
inergic [Harden et al., 1985], dopamine (D ) [Cote et al., 1985], 
2 
opiate ( ), various prostaglandins [Jakobs et al., 1984], and perhaps 
progesterone [Sadler & Mailer, 1985]. The binding of hormones (and 
neurotransmitters) to specific receptors (R or R ) initiates the 
s i 
hormonal response [Birnbaumer & Iyengar, 1982]. 
"G" or "N" proteins, the guanine-nucleotide-binding regulatory 
proteins, transfer information from receptors to their effector 
molecules. The three N proteins known at present are N and N 
s i 
(the stimulatory and inhibitory N proteins which transfer information 
from stimulatory and inhibitory receptors, respectively, to the cata¬ 
lyst of adenyl cyclase) and transducin (which transfers information 
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from retinal rod outer segment rhodopsin to cGMP-specific phosphodi¬ 
esterase) [Smigel et al., 1984 & 1985]. Both N and N are activat- 
s i 
ed by binding and hydrolysis (by GTPase), respectively, of GTP with a 
change in the conformation of the alpha, beta, and gamma subunits of 
the N protein [Hildebrandt et al., 1985; Cooper et al., 1985]. Activa- 
2+ 
tion of N and N requires Mg or another divalent cation and is 
s i 
inhibited by sodium ion [Klee et al., 1984; Jakobs et al., 1984]. The 
N -GTP complex activates the adenyl cyclase catalyst by the release 
s 
of the alpha subunit of N . The mechanism of N -GTP complex inhibi- 
s i 
tion of the adenyl cyclase catalyst is not yet known [Jakobs et al., 
1985]. 
The catalytic site of adenyl cyclase is the third component of the 
membrane complex. Activation or inactivation of the catalyst is achiev¬ 
ed by N or N , respectively, after the binding of a hormone to 
s i 
R or R , respectively. Activation of the catalyst results in the 
s i 
conversion of ATP to cAMP and therefore the increase in intracellular 
cAMP concentration. Conversely, inactivation of the catalyst inhibits 
the production of cAMP from ATP [Rail, 1982; Birnbaumer & Iyengar, 
1982; Smigel et al., 1985]. 
The adenyl cyclase system appears to exist predominantly in the 
plasma membrane (although its existence in subcellular membranous 
structures has not been excluded [Perkins, 1973]) and to exert its 
physiologic effects in various tissues by hormone-stimulated protein 
kinase activation [Beavo & Mumby, 1982}. The location and function of 
the guanyl cyclase system are not as clear [Rail, 1982]. Guanyl 
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cyclase has been found in particulate and soluble fractions [Rail, 
1982] in multiple forms [Mittal & Murad], and only a few physiologic 
functions have been shown definitively to be regulated by cGMP [Walter, 
1984]. Soluble guanylate cyclase is activated not by an N protein 
s 
but by fatty acids, free radicals, and redox agents which are believed 
to interact directly and reversibly with the enzyme [Murad et al., 
1981]. The soluble guanyl cyclase has free sulfhydryl groups and ex¬ 
ists in a heme-associated and heme-free form [Bohme et al., 1984; Ig- 
narro et al., 1984]. Because hormones have been shown to increase in¬ 
tracellular cGMP concentration but not to stimulate cell-free guanyl 
cyclase preparations it has been postulated that hormonal effects on 
cGMP are a result of a chain of reactions (stimulated by a hormone- 
2+ 
receptor interaction) involving Ca - and oxygen-dependent steps and 
eventual guanyl cyclase activation [Bohme et al., 1984]. The particu¬ 
late guanyl cyclase from sea urchin spermatozoa has been purified, but 
no mammalian guanyl cyclase has yet been purified [Garbers & Radany, 
1981] despite the fact that it has been found associated with plasma 
membranes and subcellular membranes [Murad et al., 1979]. Activation 
2+ 
of guanyl cyclase is known to require Mn and GTP [Goldberg & Had- 
dox, 1977]; further characterization of particulate guanyl cyclase 
properties awaits purification of a mammalian form. 
In most tissues the amount of guanyl cyclase and cGMP is 1/10 to 
1/100 that of adenyl cyclase and cAMP [Goldberg et al., 1973; Mittal & 
Murad, 1982]. A few specialized tissues (e.g.: retinal rod outer seg¬ 
ment [Farber, 1982]) contain significantly more guanyl cyclase and cGMP 
than adenyl cyclase and cAMP. Early studies of the regulatory function 
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of cGMP compared and contrasted its physiologic effects with those of 
cAMP and resulted in a "Yin Yang hypothesis" of cellular regulation ac¬ 
complished by opposing effects of cGMP and cAMP [Goldberg et al., 1973; 
Goldberg et al., 1975]. Subsequent studies indicated that cGMP had ef¬ 
fects opposing as well as mimicking those of cAMP [Goldberg & Haddox, 
1977; Murad et al., 1979]. The protein kinase specific for cGMP ap¬ 
pears to be located primarily in the cytoplasm and possibly subcellular 
organelles [Kuo & Shoji, 1982; Lincoln & Corbin, 1983]. Studies of 
this kinase and cGMP stimulation have implicated cGMP in regulatory 
2 + 
functions including negative feedback mediation of Ca entry in 
cells, vascular smooth muscle relaxation, platelet aggregation, and in¬ 
testinal secretion [Lincoln & Corbin, 1983; Murad et al., 1979]. cGMP 
apparently has regulatory functions mediated by other binding proteins 
besides protein kinase. A cGMP-binding protein phosphodiesterase is 
the more abundant cGMP-binding protein in platelets and rod outer seg¬ 
ments, suggesting a regulatory role for cGMP in platelet aggregation 
and visual transduction of rod photoreceptors. A cGMP-binding pro- 
tein-cAMP-phosphodiesterase is widely distributed in tissues and sug¬ 
gests a role for cGMP in controlling cAMP levels by stimulating a cAMP 
phosphodiesterase [Lincoln & Corbin, 1983]. 
The level of intracellular cyclic nucleotides, after synthesis has 
occurred, can be controlled by extrusion [Goldberg et al., 1973] or ef¬ 
flux from the cell, subcellular sequestration, or degradation by phos¬ 
phodiesterases [Appleman et al., 1982]. At least three forms (cAMP, 
cGMP, and cyclic nucleotide) of phosphodiesterase occur in different 
proportions in different tissues, and probably in different subcellular 
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locations. (More specific forms of phosphodiesterase occur only in 
certain specialized tissues, e.g.: light-activated cGMP phosphodiester¬ 
ase in rod outer segment.) All forms of phosphodiesterase have been 
located in soluble and particulate cell fractions, although the cAMP 
and cGMP phosphodiesterases appear to be primarily particulate whereas 
the cyclic nucleotide phosphodiesterase is primarily soluble or cyto¬ 
solic [Appleman et al., 1982]. The high affinity (low K ) cAMP 
m 
phosphodiesterase is inhibited by cGMP [Appleman et al., 1973]. The 
cGMP phosphodiesterase (or "high K " cyclic nucleotide phosphodiester- 
2+ m 
ase) is stimulated by Ca -calmodulin [Krinks et al., 1984]. The cyc¬ 
lic nucleotide phosphodiesterase is allosterically activated by low con 
centrations of cGMP [Wells & Hardman, 1977; Erneux et al., 1984]. A 
fourth phosphodiesterase, which is a calcium-independent form of the 
cGMP or "high K " cyclic nucleotide phosphodiesterase, also has been 
m 
identified [Manganiello et al., 1984]. 
The cyclic nucleotides are not the only second messengers. Cal¬ 
cium is "a fundamental regulator of function in all cells" [Gill, 1985] 
and may in fact be a primary messenger with the cyclic nucleotides serv 
ing as secondary messengers [Berridge, 1984]. The discovery of calmodu 
lin in 1970 [Cheung & Storm, 1982] and of calcium-dependent protein 
phosphorylations [Schulman, 1982] was followed by the characterization 
of multiple regulatory activities of calmodulin, including activation 
of the high K cyclic nucleotide (or cGMP) phosphodiesterase, activa- 
m 
tion and inhibition of adenyl cyclase, activation of some forms of gua- 
nyl cyclase, regulation of phosphorylase kinase, calcium-dependent pro¬ 
tein kinase, calcium-ATPase and other enzymes, and regulation of neuro- 
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transmitter release and cytoskeleton organization [Cheung & Storm, 
1982; Manalan & Klee, 1984]. The interaction between calcium and cyc¬ 
lic nucleotide enzymes (and the observation of cellular metabolism reg¬ 
ulation by changes in concentrations and subcellular localizations of 
calcium and the cyclic nucleotides) led some authors to speculate that 
calmodulin, as the protein mediating calcium's effects, might be the co 
ordinating regulator of calcium and cyclic nucleotide effects and there 
fore of cellular function [Watterson et al., 1984]. 
Manalan and Klee [1984] pointed out that calmodulin was a "ubiqui¬ 
tous protein" and that calcium was an intracellular messenger as impor¬ 
tant as cAMP. Berridge [1984] in an analysis of the interactions be¬ 
tween calcium and the cyclic nucleotides concluded that calcium was the 
primary activator of cellular processes and that cAMP acted only indi¬ 
rectly as a modulator of calcium-dependent reactions. cAMP can affect 
calcium influx by cAMP-dependent phosphorylation [Gill, 1985] and can 
alter calmodulin's effects by cAMP-dependent phosphorylation of calmod¬ 
ulin's target proteins [Manalan & Klee, 1984]. cAMP functions as a 
modulator by changing the clcium signal generation and calcium-depen- 
dent processes [Berridge, 1984]. Methods of intracellular communi¬ 
cation demonstrate calcium's role as the primary second messenger 
and the cyclic nucleotides' role as secondary second messengers. 
Stimulation of calcium receptors results in increased intracellular 
calcium, phosphoinositide hydrolysis, C-kinase activation, and arachi- 
donic acid release. Guanyl cyclase is activated in the calcium-recep- 
tor-stimulated cell, and prostaglandin, prostacyclin, thromboxane, and 
leukotriene products are formed from the cyclooxgenase and lipoxygenase 
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pathways. The eicosanoids act as local hormones, diffusing to other 
cells and activating adenyl cyclase and affecting calcium levels (e.g.: 
the local hormone effect of PGI in platelets is increased cAMP, 
2 
inhibition of platelet aggregation, and subsequent inhibition of cal¬ 
cium receptors) [Berridge, 1984]. 
What are the components of the calcium messenger system, and how 
is it believed to act? The intracellular calcium level is a function 
of calcium movement between the cell and the large extracellular pool 
and calcium subcellular sequestration in endoplasmic reticular and mito¬ 
chondrial membranes. The intracellular calcium levels are controlled 
by the calcium channel mediating calcium influx into the cell, calcium- 
ATPase mediating calcium efflux from the cell, and the sodium/calcium 
exchanger mediating movement of calcium both ways across the plasma mem¬ 
brane. The calcium-ATPase has a low pumping capacity but acts rapidly 
when stimulated by calcium-calmodulin, and the sodium/calcium exchanger 
has a high pumping capacity which is activated by calcium-calmodulin- 
dependent membrane-bound protein kinase. The calcium channel can be af¬ 
fected by cAMP-dependent phosphorylation resulting in an influx of cal¬ 
cium with increased cAMP levels [Carafoli, 1984]. Receptors that are 
distinct from adenyl cyclase receptors and are capable of altering in¬ 
tracellular calcium levels and calcium-dependent reactions have been 
shown to be affected by alpha , muscarinic, histaminic (H ), seroto- 
1 1 
nergic, and other agents. Binding to these receptors appears to stim¬ 
ulate a phospholipase C phosphodiesterase which cleaves polyphosphoinos- 
itol headgroups from phosphotidyl inositides (PI) [Gill, 1985]. 
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The calcium messenger system has two branches [Rasmussen et al., 
1984]: one which acts via amplitude modulation of calcium-regulated re¬ 
actions and causes initiation of cellular response (to a hormone), and 
a second which acts via sensitivity modulation of calcium-sensitive 
phospholipid-dependent protein kinase (C-kinase) and causes a sustained 
cellular response. Binding of hormone to calcium receptors results in 
a cascade of reactions beginning with the hydrolysis of PI 4,5-biphos¬ 
phate and/or PI 4-phosphate which causes activation of the two branches 
of the calcium messenger system. In the first branch the intracellular 
calcium level is increased abruptly by influx of calcium from the extra¬ 
cellular pool and release of calcium from subcellular pools. Increased 
intracellular calcium binds to calmodulin and activates calmodulin-reg¬ 
ulated enzymes, with protein kinase activation resulting in phosphoryl¬ 
ation of numerous cellular proteins and plasma membrane calcium pump ac¬ 
tivation resulting in lowered calcium levels by efflux and intramito- 
chondrial sequestration. In the second branch the cell membrane diacyl- 
glycerol content is increased, C-kinase is bound to the plasma membrane 
and thereby activated, and C-kinase activation results in phosphoryl¬ 
ation of other cellular proteins and a sustained cellular response (to 
the hormone) [Rasmussen et al., 1984]. Hormones and extracellular mes¬ 
sengers regulate cell activity by increasing cytosolic calcium concen¬ 
tration. Calcium acts as a "universal intracellular messenger" through 
the calmodulin and C-kinase branches [Rasmussen et al., 1984]. cAMP 
can alter the action of calcium by affecting some of the calmodulin and 
C-kinase branch reactions. 
Although calcium may be a more important second messenger than 
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previously realized it is apparent that both calcium and cyclic nucleo¬ 
tides serve as intracellular messengers regulating the physiologic ef¬ 
fects of hormones and other extracellular messengers. The complex in¬ 
teractions between these intracellular messengers and with their target 
enzymes and proteins results in an overall cellular metabolism. Other 
roles and interactions for these and other intracellular messengers 
must exist, and further studies of cellular mechanisms and their compo¬ 
nents undoubtedly will lead to an even more complex picture of cellular 
metabolism and extra- to intracellular communication. Already other 
ions besides calcium, including chloride and sodium, have been implica¬ 
ted as regulators of cyclic nucleotide activity [Rodbell, 1984]. 
The numerous components of the cyclic nucleotide and interrelated 
calcium messenger systems allow for several modes of down-regulation 
and self-modulation. Some type of down-regulation of receptors, nuc¬ 
leotide regulatory proteins, and phosphodiesterases is known to occur. 
Persistent stimulation of beta-receptors causes a decrease in cAMP 
production and the physiologic effect. Beta-receptor desensitization 
can be homologous or heterologous, blunting the response of the recep¬ 
tor to a specific hormone or to all agonists, respectively. Homologous 
desensitization is not cAMP-mediated and may involve uncoupling of the 
receptor from adenyl cyclase or translocation of the receptor from the 
plasma membrane after receptor phosphorylation. Heterologous desensiti¬ 
zation appears to involve receptor uncoupling and phosphorylation and 
possibly nucleotide regulatory protein phosphorylation. Receptor phos¬ 
phorylation can be activated by cAMP-dependent kinase, calcium-sensi¬ 
tive C-kinase, and other protein kinases [Sibley & Lefkowitz, 1985; 
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Lefkowitz et al., 1984; Perkins et al., 1982]. Other receptors could 
be desensitized by mechanisms similar to homologous and heterologous 
beta-receptor desensitization. 
Counterregulation of nucleotide protein adenyl cyclase activation 
is accomplished by N activating N as well as the adenyl cyclase 
s i 
catalyst [Jakobs et al., 1985]. Sodium ion apparently modulates adenyl 
cyclase activity by an action on N and perhaps R [Rodbell, 1984; 
i i 
Jakobs et al., 1985]. 
cAMP phosphodiesterase conversion to a less-active form by its own 
substrate cAMP could be considered yet another example of counterregu¬ 
lation [Robison et al., 1984]. Another form of down-regulation of hor¬ 
mone-stimulated physiologic effects occurs with activation of calmodu¬ 
lin-stimulated cyclic nucleotide phosphodiesterase during chronic beta- 
adrenergic stimulation [Manalan & Klee, 1984], and with decreasing the 
K of calmodulin-stimulated phosphodiesterase for calmodulin in the 
0.5 
presence of cyclic nucleotides [Krinks et al., 1984]. Stimulation of 
cAMP phosphodiesterase by cGMP may be a type of self-regulatory process 
in the cell. 
In addition to being prime sites for counterregulation, phosphodi¬ 
esterases appear to be the target of some hormones' primary effects. 
Muscarinic cholinergic receptor stimulation appears to exert its second 
messenger effect not only by activating the N protein but also by 
i 
activating the calmodulin-stimulated phosphodiesterase [Harden et al., 
1985]. Insulin appears to antagonize the effect of glucagon on the 
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liver by activating the cAMP phosphodiesterase [Housley et al., 1984; 
Appleman et al., 1984]. 
This picture of the complex second messenger system, with its 
multiple components, messengers, regulatory reactions, and counter- 
regulatory mechanisms, provides a background against which to consider 
phosphodiesterase inhibition and its effects. Phosphodiesterases de¬ 
grade cAMP and cGMP and thereby bring an end to the intracellular hor¬ 
monal message. In their multiple forms with unique modes of regulation 
(positive and negative cooperativity and calmodulin stimulation) they 
appear to provide the possibility of "finely controlled, multifaceted 
regulation of cyclic nucleotide metabolism" [Manganiello, 1984; 
Vaughan, 1981]. Phosphodiesterases should be able to monitor the inten¬ 
sity and duration of the intracellular message [Strada et al., 1984] 
and therefore the physiologic effect of the first messenger. Phospho¬ 
diesterase inhibitors selective for a particular form of phosphodies¬ 
terase theoretically would alter the concentration of a specific cyclic 
nucleotide in a tissue (depending upon the percentage and regulatory 
importance of each phosphodiesterase form in that individual tissue) 
and would have potential to elicit specific cellular responses [Weiss, 
1975; Hidaka & Endo, 1984; Dudkin et al., 1983]. Phosphodiesterase 
inhibitors therefore would be able not only to mimic or potentiate the 
action of extracellular messengers (e.g.: hormones, neurotransmitters) 
[Wells & Kramer, 1981] but also to treat diseases for which altered 
cyclic nucleotide metabolism is responsible [Weiss & Hait, 1977]. 
The more well-known phosphodiesterase inhibitors, methylxanthines 
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and papaverine, have been used to increase cyclic nucleotide levels and 
to effect physiologic changes such as smooth muscle relaxation [Chasin 
& Harris, 1977]. These agents, like many other phosphodiesterase in¬ 
hibitors, often cause nonspecific elevations of cAMP and cGMP in var¬ 
ious tissues and often exert physiologic effects through actions other 
than phosphodiesterase inhibition [Chasin & Harris, 1977; Wells & Kra¬ 
mer, 1981]. More selective phosphodiesterase inhibitors have been 
sought [Weiss & Hait, 1977; Appleman et al., 1982], and some of those 
which have been synthesized have been shown to potentiate the physiolo¬ 
gic effects (e.g.: bovine coronary artery relaxation) of adenyl cyclase 
and guanyl cyclase activators [Poch & Reich, 1983; Lorenz & Wells, 
1983]. A more intriguing use of selective inhibitors has been in the 
treatment of diseases characterized by cyclic nucleotide metabolism 
abnormalities. 
Cyclic nucleotides mediate numerous physiologic processes, and 
abnormalities in cyclic nucleotide metabolism are responsible for 
pathophysiologic processes. Abnormalities in cyclic nucleotide met¬ 
abolism can occur at any level, with abnormalities in hormones, recep¬ 
tors, nucleotide proteins, catalytic sites, phosphodiesterases, protein 
kinases, calmodulin or intracellular ions possibly responsible for 
pathophysiologic processes [Harriet et al., 1984]. Phosphodiesterase in¬ 
hibitors have been used to treat disease processes characterized by de¬ 
creased levels of cAMP or cGMP, whether the cyclic nucleotide metabol¬ 
ism abnormality was known to be at the level of cyclic nucleotide syn¬ 
thesis or degradation. Various disease conditions improved by phospho¬ 
diesterase inhibition include psoriasis, asthma, certain inflammatory 
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states, adult onset diabetes, leukemia and other malignancies [Weiss & 
Hait, 1977]. As the roles of cyclic nucleotides in physiology and 
pathophysiology become better defined the effective employment of se¬ 
lective phosphodiesterase inhibitors becomes more likely. More selec¬ 
tive phosphodiesterase inhibitors might have potential not only in the 
diseases mentioned above but also in abnormalities of neurotransmission 
in which the calmodulin-stimulated phosphodiesterase plays a role [Ap- 
pleman et al., 1982] or in retinal degenerative diseases in which defi¬ 
cient levels of cGMP phosphodiesterase have been implicated [Farber, 
1982] . 
This study was concerned with the effects of a reportedly selec¬ 
tive phosphodiesterase inhibitor (HL725, Hoescht-Roussel Pharmaceuti¬ 
cal, Inc.) on rabbit IOP and ciliary process cyclic nucleotide produc¬ 
tion. Rabbit ciliary processes contain a beta-adrenergic receptor- 
adenyl cyclase complex which is postulated to effect decreases in 
aqueous humor formation and IOP upon activation by agents which are 
known to increase ciliary process intracellular cAMP levels [Gregory et 
al., 1981; Caprioli & Sears, 1984]. It was theorized that a phosphodi¬ 
esterase inhibitor shown (at a certain concentration range) to be selec¬ 
tive for cAMP phosphodiesterase [Ruppert & Weithmann, 1982; Ruppert, 
1983] could selectively increase ciliary process cAMP and result in a 
decreased IOP. The agent (HL725) did cause small decreases in IOP when 
topically applied and did slightly potentiate the hypotensive effect of 
isoproterenol when injected intravitreally, but did not decrease IOP 
when administered intravitreally. Measurements of ciliary process cyc¬ 
lic nucleotide production demonstrated that HL725 increased cAMP and 
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cGMP levels in the same range of HL725 concentration. Let us examine 
more closely HL725's effects on IOP and on ciliary process cyclic nuc¬ 
leotide production as well as our knowledge of cyclic nucleotide system 
in the eye and agents affecting this system. 
Adenyl cyclase and beta receptors have been identified in the epi¬ 
thelial membranes of rabbit ciliary processes [Tsukahara & Maezawa, 
1978; Bromberg et al., 1980]. Guanyl cyclase activity has been demon¬ 
strated in the soluble and particulate fractions of rabbit ciliary pro¬ 
cesses [Gregory, personal communication], indicating the probable exis¬ 
tence of both cytosolic and membrane-associated guanyl cyclase in this 
tissue. 
As early as 1966 Shanta et al. documented the presence of phospho¬ 
diesterase in the apical nonpigmented epithelial cells of the ciliary 
processes. Studies at the time were unable to distinguish between the 
various forms of phosphodiesterase, so one can only speculate as to the 
type or types of phosphodiesterase activity which that study showed to 
be present in various ocular tissue including ciliary processes, con¬ 
junctiva, corneal stroma and endothelium, anterior chamber angle endo¬ 
thelium, retinal rod and cone outer and inner segments, outer limiting 
membrane, outer and inner nuclear layer, outer and inner plexiform lay¬ 
ers, and the choroid. One might speculate on the basis of present know¬ 
ledge [Farber, 1982] that the retinal rod outer segments would contain 
a calcium-calmodulin-independent cGMP phosphodiesterase and a light-ac¬ 
tivated cAMP phosphodiesterase [Yamazaki et al., 1985] and the corneal 
epithelium might contain some forms of cAMP phosphodiesterase [Farber, 
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1982], and on the basis of the present study that the ciliary processes 
must contain cAMP and cGMP phosphodiesterases (or possibly the cGMP- 
stimulated cyclic nucleotide phosphodiesterase). Studies by Gregory 
and Bausher [personal communication] indicate the presence of phospho¬ 
diesterases degrading cAMP and cGMP in soluble and particulate frac¬ 
tions of rabbit ciliary processes. No studies have been done to fur¬ 
ther characterize and more specifically indentify and localize the 
rabbit ciliary process phosphodiesterases. 
Why did HL725 in one concentration range stimulate both cAMP and 
cGMP production in the rabbit ciliary processes? HL725 was shown to 
have potent platelet aggregation inhibitory and hypotensive vasodil- 
atory properties not mediated by alpha- or beta-adrenergic receptors 
[Lai et al., 1981 & 1984; Ruppert & Weithmann, 1982], and because it 
had a strong inhibitory effect on cAMP phosphodiesterase in platelets 
and vascular tissues it was proposed that its physiologic effects were 
mediated by cAMP phosphodiesterase inhibition [Lai et al., 1981]. Fur¬ 
ther studies of HL725's effects on platelet cyclic nucleotide phosphodi¬ 
esterases indicated that it was an effective inhibitor of cAMP and cGMP 
phosphodiesterase in platelets, with cAMP phosphodiesterase inhibited 
-12 -8 
at concentrations betweeen 10 and 10 M and cGMP phosphodiester- 
-8 -5 
ase inhibited between 10 and 10 M HL725. Platelet cAMP produc- 
-7 -4 
tion was stimulated at concentrations between 10 and 10 M, and 
-13 
platelet aggregation was inhibited at concentrations between 10 
-10 
and 10 M. [Ruppert & Weithmann, 1982]. An additional investigat¬ 
ion further characterized HL725's effects on various platelet phospho¬ 
diesterase fractions. HL725 inhibited high affinity cGMP, low affinity 
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cyclic nucleotide, and high affinity cAMP phosphodiesterases from plate¬ 
let extract separated by DEAE-Biogel A chromotography (i.e.: soluble 
fraction phosphodiesterases). cGMP phosphodiesterase (PDE) was in- 
-7 -7 
hibited with K = 4 x 10 M and IC = 7 x 10 M at 0.5 microM 
i 50 -7 
cGMP; cyclic nucleotide PDE with K = 4 x 10 M and IC = 6 x 
-7 i 50 -10 
10 M at 10 microM cGMP; and cAMP PDE with IC = 2-5 x 10 M at 
50 
0.5 microM cAMP (all molarity values represent HL725 concentration un¬ 
less otherwise specified). The washed particulate fraction also con- 
-6 
tained PDEs inhibited by HL725: a cGMP PDE with IC = 1.5 x 10 M 
50 -7 
(at 0.5 microM cGMP) and a cAMP PDE with IC = 3-7 x 10 M (at 0.5 
50 
microM cAMP). Although, as the author reports, there is "a remarkable 
split between the inhibitory effects of HL725 upon the low K (high 
m 
affinity) cAMP and cGMP phosphodiesterase activities" and the cytosolic 
and membrane-associated cAMP PDE inhibition may be responsible for 
HL725's antiaggregatory effects [Ruppert, 1983], it is obvious that 
HL725 may be affecting cGMP and low affinity cyclic nucleotide phospho¬ 
diesterases and exerting some of its effects by those actions as well. 
Platelet function and smooth muscle relaxation are regulated by 
changes not only in cAMP but also in cGMP. It has been known for years 
that platelet aggregation is inhibited by increases in cAMP, but plate¬ 
let aggregation recently has been shown to be inhibited by increases in 
cGMP as well [Harriet et al., 1984; Hidaka & Endo, 1984; Bohme et al., 
1984]. Vascular smooth muscle relaxation also is caused by increases 
in both cAMP and cGMP [Harriet et al., 1984; Hidaka & Endo, 1984; Bohme 
et al., 1984]. It is apparent therefore that both cAMP and cGMP in¬ 
creases can mediate vascular smooth muscle relaxation and platelet ag- 
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gregatory inhibition. Platelets, lung tissue, vascular smooth muscle, 
and rod outer segments all contain a specific cGMP binding protein 
which has PDE activity; this protein is distinct from calmodulin-sensi¬ 
tive and cGMP-stimulated PDEs [Hamet et al., 1984]. This is only one 
form of PDE present in platelets and vascular smooth muscle which along 
with the other PDEs present must be involved in cAMP and cGMP regula¬ 
tion in these tissues. Recent reports confirm that activation of gua- 
nyl cyclase brings about smooth muscle relaxation [Ignarro & Kadowitz, 
1985; Rapoport et al., 1983]. A cGMP-dependent protein kinase has been 
located in vascular smooth muscle cell membranes, and smooth muscle re¬ 
laxation appears to involve removal of calcium from the cytoplasm [Lin¬ 
coln & Johnson, 1984]. cGMP apparently activates cGMP-dependent pro¬ 
tein kinase which then stimulates sarcolernmal calcium extrusion ATPase 
[Popescu et al., 1985]. 
HL725's potency in inhibiting platelet aggregation and inducing 
vascular smooth muscle relaxation may be dependent on its inhibition of 
cAMP PDEs, cGMP PDEs, or both. The selectivity of phosphodiesterase in¬ 
hibitors can vary from one tissue to another [Kramer et al., 1977]. 
The resultant physiologic effect of a phosphodiesterase inhibitor on a 
tissue will be dependent on the ratio of various forms of PDE in that 
tissue and the selective effect of the phosphodiesterase inhibitor on 
that tissue's PDEs. The proportional increases in cAMP and cGMP as 
well as the dependence of the intracellular message on calcium can 
affect the cell's physiologic response [Goldberg et al., 1973]. HL725 
appears to have a selective effect on cAMP and cGMP phosphodiesterases 
depending on its concentration in platelets. Its antiaggregatory ef- 
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feet may be the result of increases in cAMP or cGMP or both. HL725's 
vasodilatory properties could be dependent on increases of one or both 
of the cyclic nucleotides. 
Although one must consider the limitations of measurements of 
gross tissue cyclic nucleotide levels at one point in time (changes in 
cyclic nucleotide concentrations may occur rapidly, measurement in an 
entire tissue provides only a gross picture of the individual cellular 
and subcellular levels of cyclic nucleotides, and the physiologic ef¬ 
fects may be dependent on the rate and ratio of the changes as well as 
the involvement of other intracellular messengers), it can be concluded 
from the measurements of cyclic nucleotide levels that HL725 increases 
cAMP and cGMP above basal levels in ciliary processes. HL725 is not a 
selective inhibitor of ciliary process phosphodiesterases. Is the 
small ocular hypotensive effect of HL725 a result of simultaneous stim¬ 
ulation of both cyclic nucleotides? If cAMP and cGMP have similar in¬ 
fluences on AHF, assuming that HL725 is penetrating the ciliary process 
cells and effecting increases in both cyclic nucleotides one would ex¬ 
pect to see significant decreases in IOP from diminished AHF. The ques¬ 
tion of cellular penetration will be addressed later. For the moment 
let us assume that HL725 is simultaneously increasing both cyclic nuc¬ 
leotide levels in ciliary processes in vivo as it does in vitro. What 
are the possible explanations for it causing only small changes in 
IOP? Increases in cGMP may be activating cGMP-stimulated cAMP PDE 
thereby counteracting HL725's increases of cAMP by causing a delayed 
stimulation of cAMP degradation. The new ratio of cAMP to cGMP brought 
about by HL725 may result in only minor cAMP-mediated effects (and 
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therefore small decreases in IOP). Increases in a cGMP may mediate ocu¬ 
lar hypertensive effects which are counteractive to the cAMP-mediated 
ocular hypotensive effects. (Indeed one group of investigators 
reported that topical application of agents known to stimulate guanyl 
cyclase resulted in increased aqueous humor cGMP concentrations and IOP 
[Krupin et al., 1977], although other investigators were unable to con¬ 
firm these findings [Sears, 1984].) Increases in cGMP may be attribu¬ 
table to vascular smooth muscle cGMP level increases in the ciliary 
processes, not to cGMP presence in the NPE cell. 
HL725 may be affecting the cyclic nucleotide levels in other ocu¬ 
lar tissues and thereby changing other components of aqueous humor 
dynamics which could counteract a reduction in AHF. Cyclic nucleotides 
serve as intracellular messengers regulating the cellular function of 
many other ocular tissues besides the ciliary process nonpigmented epi¬ 
thelium. They are involved in the regulation of ocular functions such 
as retinal visual transduction, corneal chloride pump, blood aqueous 
barrier stability, ciliary muscle relaxation, and perhaps aqueous out¬ 
flow [Farber, 1982]. Undoubtedly many other roles for cyclic nucleo¬ 
tides in regulation of ocular tissue function will be discovered. 
Based only upon the presently available data it is difficult to draw a 
unifying hypothesis concerning the intracellular messenger system and 
its control of AHF and IOP. The ciliary process adenyl cyclase-recep¬ 
tor complex has introduced a possible mechanism of AHF control whereby 
adenyl cyclase stimulants effect decreases in AHF (and IOP). What are 
the ocular hypo- or hypertensive effects of other agents known to stim¬ 
ulate or inhibit adenyl cyclase in the classic model of the intracel- 
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lular second messenger system previously outlined? Dopamine can cause 
ocular hypotension (and this effect can be blocked by haloperidol) 
[Shannon et al., 1976], but possible involvement of dopamine receptors, 
which can be stimulatory (D ) or inhibitory (D ) of adenyl cyclase, 
1 2 
have not been studied in ciliary process membranes. Alpha -adrenerg- 
2 
ic agonists lower IOP [van Zwieten & Zimmermans, 1984] and AHF [Lee et 
al., 1984], and both alpha and alpha antagonists also lower IOP 
1 2 
[Mittag et al, 1985]. In the classic model, alpha receptors are in- 
2 
hibitory of adenyl cyclase and would be expected to decrease cAMP and 
either prevent ocular hypotension or cause hypertension. Beside the 
studies correlating beta-agonist, cholera toxin, and forskolin stimu¬ 
lation of adenyl cyclase with increases in cAMP and subsequent de¬ 
creases in AHF, it is difficult to propose a correlation between other 
agents, stimulatory and inhibitory receptors, effects on cAMP and AHF 
based upon presently available information. It will be of interest to 
attempt localization of dopamine, adenosine, muscarinic cholinergic, 
and prostaglandin receptors coupled to adenyl cyclase in the ciliary 
processes and to correlate the effects on AHF with stimulation of these 
receptors (if present). 
What of the possible role of cGMP as an intracellular messenger in 
ciliary process nonpigmented epithelial cells regulating AHF? Little 
information is available on cGMP stimulation and ocular tension. As 
previously mentioned, one study indicated that agents stimulating the 
production of cGMP resulted in ocular hypertension [Krupin et al., 
1977], although this finding has not been duplicated [Sears, 1984]. 
Guanyl cyclase and a cGMP phosphodiesterase do exist in ciliary pro- 
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cesses [Gregory & Bausher, personal communication], and HL725 causes an 
increase in ciliary process cGMP. Does cGMP serve as an intracellular 
messenger in ciliary processes, involved in regulation either of AHF or 
of some other physiologic process, or is guanyl cyclase a non-function¬ 
al enzyme present in the ciliary processes only as a remnant of its 
neuroectodermal layer origin (the layer of the secondary optic vesicle 
from which the sensory retina with its functional guanyl cyclase devel¬ 
oped) [Newell, 1982]? In light of cGMP's stimulation by ascorbate [Mur 
ad et al., 1981] and the suggestion of active secretion of ascorbic 
acid across the ciliary process [Sears, 1980] with ascorbic acid trans¬ 
port negatively correlated with AHF [Sears, 1980; Bar-Ilan, 1984], it 
is possible that intracellular ascorbate concentrations controlled by 
an ascorbate transport mechanism might regulate increases in cGMP and a 
subsequent increase in IOP (or other physiologic effect). Another pos¬ 
sibility is that cGMP might act as a monitor of the redox state of the 
tissue, preventing oxidation or destruction (by free radicals) of cel¬ 
lular components [Murad et al., 1979]. 
Could calcium also function as an intracellular messenger in the 
ciliary process nonpigmented epithelium? One of the phosphodiesterases 
in the ciliary processes could be a calcium-calmodulin-stimulated phos¬ 
phodiesterase. Vanadate, an agent known to affect not only the sodium/ 
potassium-ATPase but also the calcium-ATPase [Manalan & Klee, 1984], 
has been shown to decrease AHF and IOP [Podos et al, 1984; Mittag et 
al, 1984]. The sodium/potassium-ATPase is known to be present on the 
lateral interdigitations of NPE cells and to be involved in the secre¬ 
tory mechanism responsible for AHF [Sears, 1980], and the calcium- 
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ATPase may also be involved. Calcium is responsible for the regulation 
of so many cellular functions [Rasmussen et al., 1984] that it is prob¬ 
able to have a role in the function of the ciliary process NPE and in 
AHF. 
The model of the second messenger system regulating the NPE cell 
is far from complete. An adenyl cyclase-receptor complex present in 
the NPE plasma membrane promotes decreases in AHF and IOP when stimu¬ 
lated by beta-agonists, cholera toxin, and forskolin. In the ciliary 
processes phosphodiesterases are present, though their types and ratio 
are not known. Increases in cGMP in the ciliary processes can be stim¬ 
ulated, but its location and role, if any, are not known. A possible 
role for calcium as an associated intracellular messenger has yet to be 
defined. It will be exciting in the future to attempt to locate addi¬ 
tional (inhibitory as well as stimulatory) adenyl cyclase receptors (by 
radioligand binding or other methods), to characterize and localize var¬ 
ious forms of phosphodiesterase (with monoclonal antibodies [Hurwitz et 
al., 1984] and enzymatic studies), to localize guanyl cyclase and inves¬ 
tigate its possible functional role, and to study the possible activity 
of calcium within the ciliary processes and individual cell types. As 
more information is obtained a clearer picture of the intracellular mes¬ 
senger system and its regulation of AHF will be able to be constructed. 
To conclude the discussion of HL725's minimal hypotensive effect, 
one must consider the problems of ocular and cellular penetration or 











is a hydrochloride salt of the isoquinoline derivative drawn above. It 
is relatively insoluble in saline and forms a flocculent precipitate in 
BSS. The compound's relative insolubility in saline required that sus¬ 
pensions of the substance be employed at high concentrations. To pro¬ 
long contact of the substance with the cornea and to increase penetra¬ 
tion, a dispersion in BSS and hydroxypropyl methylcellulose was pre¬ 
pared. Unfortunately HL725 formed a flocculent precipitate in BSS 
which may have been a less reactive (and perhaps less potent) salt of 
the substance. Relatively poor ocular bioavailability and cellular 
penetration might be cited as a possible explanation for this com¬ 
pound's only slight effectiveness as an ocular hypotensive agent. The 
agent was effective in vitro in increasing ciliary process cAMP and 
cGMP levels and therefore must have penetrated the cells sufficiently 
to cause phosphodiesterase inhibition, although one can only speculate 
as to what extent or in what concentrations the compound crossed the 
plasma membrane. The substance did exert slight ocular hypotensive 
effects when applied topically and did potentiate the effects of topi¬ 
cally applied isoproterenol when injected intravitreally, so one could 
presume that some amount of HL725 reached the site of action in the 
\ 
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ciliary processes when administered topically and intravitreally. Poor 
ocular bioavailability and cellular penetration may partially account 
for HL725's minimal effectiveness in mimicking a cAMP-mediated response 
and in potentiating the effects of an agent known to stimulate adenyl 
cyclase. 
Why did intravitreal injections of HL725 result in no changes in 
IOP but potentiate the hypotensive effect of isoproterenol? One would 
expect that any problem with bioavailability with intravitreal injec¬ 
tions would be equal in the presence or absence of isoproterenol. 
HL725 increased cAMP and cGMP levels in the rabbit ciliary processes in 
vitro. The cyclase activity ratio (ratio of cAMP activity in the pres¬ 
ence of agent to the basal cAMP activity) varied between 1.7 and 4.2, 
-7 -4 
with HL725 concentrations between 10 and 10 M, whereas the cyc¬ 
lase activity ratio previously reported for isoproterenol was close to 
6 [Caprioli & Sears, 1984]. Increases of cAMP resulting in cyclase ac¬ 
tivity ratios between 2 and 3 should be sufficient to maximally acti¬ 
vate protein kinases [Butcher, 1984]. It is possible that the amount 
of HL725 actually reaching the ciliary process phosphodiesterases when 
injected intravitrally was insufficient to stimulate cAMP increases 
two- to three-fold above basal but was sufficient to potentiate the 
response brought about by low concentrations (submaximal) of isoproter¬ 
enol . 
Early in the course of this study, when HL725 had shown only small 
ocular hypotensive effects and its effects on ciliary process cyclic nu¬ 
cleotide levels were unknown, it was postulated that HL725 might cause 
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only small effects because of low basal cAMP levels. If basal turnover 
of cAMP were low then phosphodiesterase inhibition might result in cAMP 
stimulation insufficient to cause a significant physiologic (IOP) ef¬ 
fect. The IOP circadian rhythm suggested the possibility of a circadi¬ 
an rhythm of ciliary process cAMP levels (possible mediators of AHF) as 
well. Administration of HL725 at the time of a cAMP level nadir or to 
a tissue with low basal cAMP turnover would be unlikely to result in 
dramatic cAMP increases. Submaximal doses of isoproterenol might stim¬ 
ulate the adenyl cyclase system enough to give the phosphodiesterase 
inhibitor an opportunity to work. HL725 was employed in conjunction 
with isoproterenol (in a dose shown to be minimally but significantly 
hypotensive, and therefore capable of providing submaximal stimulation 
of the cyclase system), and it did potentiate isoproterenol's ocular 
hypotension, but the delta IOP (treated eye IOP minus control eye IOP) 
was not remarkably different from that seen with topical HL725 alone. 
HL725 probably caused small changes in IOP not because of low basal 
cAMP turnover in the ciliary processes but because it nonselectively 
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